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1 Introduction 
Sulfur-containing compounds, especially sulfone derivatives (Figure 1), have 
been widely used as anticancer, anti-inflammatory and antiviral agents in 
pharmacology.1 Famous sulfur-containing drugs include penicillin with a sulfide 
group, esomeprazole with a sulfoxide group, dapsone with a sulfone group, prontosil 
with a sulfonamide group and far more other drugs unmentioned here (Figure 1). 
Recently, sulfoximines have attracted increasing attention in medicinal chemistry due 
to the similar structure of sulfone (see 1.5.3 Bioactive compounds).  
 
 
Figure 1: Several sulfur-containing compounds and famous sulfur-containing drugs. 
 
Compared to the sulfone-based drugs, sulfoximines or sulfilimines are not as 
common. In order to enlarge the library of sulfoximine- and sulfilimine-based 
bioactive compounds, broadening the knowledge about sulfoximines is essential. 
Therefore, understanding the history and development of sulfoximines is the key. 
Hence, sulfoximines will be introduced below. 
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1.1 The discovery of sulfoximines 
The first sulfoximine was reported in 1949 by Bentley and co-workers.2 An 
unknown compound was formed when they treated wheat with NCl3. In 1950, it was 
first isolated3 and identified4 as methionine sulfoximine (11 MSO, Figure 2), which 
was formed by the reaction of NCl3 and methionine, a sulphur-containing amino acid 
included in zein.  
 
  
Figure 2: Methionine sulfoximine 11 (MSO). 
 
Subsequently, methionine sulfoximine was synthesized by imination of 
methionine sulfoxide with HN3 (Scheme 1, Eq.1).5a Recently, MSO was prepared by 
Bolm from methionine derivatives under mild and safe imidation/oxidation 
conditions.5b  
 
 
Scheme 1: Synthesis of MSO according to a method reported by Bentley and 
co-workers.5a 
 
Due to its bioactivity, the discovery of methionine sulfoximine attracted a great 
deal of attention from chemists and biologists. Since then, innumerable research 
projects have been carried out in the field of sulfoximines.  
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1.2 The preparation of sulfoximines 
Two main routes are used for the preparation of sulfoximines 6 from sulfides 1 
(Scheme 2).6 In the first route, sulfides are oxidized to form sulfoxides 4, which are 
subsequently iminated to afford sulfoximines. In the second one, sulfides are 
iminated firstly to form sulfilimines 5. Their oxidation forms the corresponding 
sulfoximines. As a consequence, preparations of sulfoxides and sulfilimines are keys 
to the synthesis of sulfoximines. 
 
 
Scheme 2: Two routes for the preparation of sulfoximines. 
1.2.1 Sulfoxides as intermediates 
1.2.1.1 Sulfoxide Syntheses 
Due to their extensive application in synthesis and biological chemistry, 
numerous methods exist for the preparation of sulfoxides. They can lead to racemic or 
enantiomerically enriched products depending on the protocol. 
1.2.1.1.1 Racemic sulfoxidation 
Oxidants for the oxidation of sulfides to racemic sulfoxides include 
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m-chloroperoxybenzoic acid (m-CPBA),7 Chloramine-T combined with a catalytic 
amount of acetic acid in methanol,7b the combination of H2O2 with AcOH,8 and H2O 2 
in H2O 9 (Scheme 3). 
 
 
Scheme 3: Oxidation of sulfides. 
1.2.1.1.2 Asymmetric sulfoxidation 
Initially, optically active sulfoxides were prepared by a method reported by 
Andersen in 1962. It involved a nucleophilic substitution of (-)-methyl 
(-)-p-toluenesulfinate (13) by ethylmagnesium iodide to afford (+)-ethyl p-tolyl 
sulfoxide (14) (Scheme 4).10,11 The resulting sulfoxide was obtained in moderate yield, 
but with high enantiomeric excess.  
 
 
Scheme 4: Synthesis of optically active sulfoxides according to Andersen.10,11 
 
In 1984, the preparation of enantioenriched sulfoxides by the use of a 
combination of Ti(Oi-Pr)4, (R,R)-diethyl tartrate, t-BuOOH and water was reported by 
Kagan and co-workers.12 Most of the products were obtained in good to excellent 
yields and with good ee values (Scheme 5).  
 
Scheme 5: The asymmetric oxidation of sulfides using a titanium reagents.12 
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Since then, considerable success has been reached in asymmetric sulfoxidation. 
Often, transition metal have played a major role.13-17 
In 1995, another method for the preparation of enantiomerically enriched 
sulfoxides from sulfides was reported by Bolm and co-worker using VO(acac)2 as 
catalyst, compounds 15a-d as ligands and H2O2 as oxidant. Ligand 15b proved to be 
the best one (Scheme 6). The optically active sulfoxides were formed in good to 
excellent yields and high enantioselectivities (up to 85%) at room temperature in 
DCM.18 
 
 
Scheme 6: The preparation of enantiopure sulfoxides catalyzed by VO(acac)2.18 
 
In 2011, the combination of vanadium complex 16 and H2O2 was used to prepare 
allyl aryl sufoxides by Zhao and co-workers (Scheme 7).19  
 
Scheme 7: The preparation of allyl aryl sufoxides catalyzed by a vanadium 
complex.19 
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Various products were obtained in moderate yields with excellent ee values (up 
to 97%) under mild reaction conditions. 
In 2003, the iron-catalyzed asymmetric oxidation of sulfides to sulfoxides using 
a combination of aq. H2O2, Fe(acac)2 and ligand 15 at room temperature in DCM was 
reported by Bolm and co-worker (Scheme 8).20 Due to easy accessibility and 
non-toxicicity, iron is a good choice compared to other metals. In 2004, a significant 
improvement (up to 78% yield, 96% ee) was achieved by using 10 mol% of 
4-methoxybenzoic acid or lithium 4-methoxybenzoate as additive.21, 22 
 
 
Scheme 8: The iron-catalyzed asymmetric oxidation of sulfides.20 
 
In 2012, the asymmetric oxidation of sulfides catalyzed by copper salts was 
reported by Maguire (Scheme 9).23 Various optically active sulfoxides were obtained 
in good to excellent yields. However, the ee values were only moderate. 
 
Scheme 9: The asymmetric oxidation of sulfides catalyzed by copper salts.23 
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1.2.1.2 The oxidative imination of sulfoxides 
1.2.1.2.1 Use of azides 
The preparation of sulfoximines by imination of sulfoxides with hydrazoic acid 
was reported by Reiner24 and Bentley5a,25 (Scheme 10). A variety of N-H sulfoximines 
(including S,S-diphenyl sulfoximine and various S-methyl-S-aryl sulfoximines) were 
prepared in low yields (about 20%) by Reiner and co-workers , who treated sulfoxides 
with hydrazoic acid in the presence of conc. H2SO4.24 As an improvement, the 
combination of NaN3 and conc. H2SO4 was used instead of HN3 for the preparation of 
N-H sulfoximines by Bentley.25  
 
 
Scheme 10: The preparation of N-H sulfoximines by imination of sulfoxides. 
 
   In 1967, TsN3 was used as nitrene source in the preparation of N-SO2Ar 
sulfoximines by Kahn and Kwart.26 Actually, the N-SO2Ar S-methyl-S-methyl 
sulfoximines were obtained unexpectedly when the decomposition of TsN3 was 
investigated using DMSO as solvent. Since then, TsN3 served as the nitrene source in 
the preparation of various N-SO2Ar sulfoximines. The corresponding N-H 
sulfoximines were obtained by removal of the ArSO2 group with conc. H2SO4 
(Scheme 11).27-31  
 
 
Scheme 11: The preparation of N-H sulfoximines using TsN3 as nitrene source.26 
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In 1998, the correspondingly N-Boc sulfoximines was obtained after the 
imination of sulfoxides with t-butyloxycarbonyl azide (BocN3) by Korber and Bach 
(Scheme 12).32 In this reaction, FeCl2 served as catalyst and N-H sulfoximines were 
obtained by removing the Boc group under acidic conditions.  
 
 
Scheme 12: Use of BocN3 in the preparation of N-Boc sulfoximines.32 
 
However, the explosiveness of the azide reagents along with the harsh reaction 
conditions, such as high temperature, limited this method. 
1.2.1.2.2 Use of O-mesitylenesulfonylhydroxylamine (MSH) 
In 1972, O-mesitylenesulfonylhydroxylamine (MSH) was introduced for the 
imination of sulfoxides and the preparation of N-H sulfoximines was improved 
significantly (Scheme 13).33 Further investigations of this method have been done by 
Johnson34 and Bolm35. It was found that optically active sulfoximines were obtained 
when enantiomerically enriched sulfoxides were used as substrates.35 This method has 
several advantages, including simple procedure, easy work-up, a broad substrate 
scope, satisfying yields and mild reaction conditions. However, the application of this 
method was limited due to explosiveness of MSH.   
 
 
Scheme 13: Use of MSH in the preparation of N-H sulfoximines. 
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1.2.1.2.3 Use of sulfonamides 
 The preparation of sulfoximines from sulfoxides using sulfonamides as nitrene 
sources was reported by Komori and co-workers at 1971.36 The N-sulfonyl 
sulfoximines were obtained in low to moderate yields by heating a combination of 
sulfonamide, an equimolar amount of Pb(OAc)4 and DMSO at 50 oC for 3 hours 
(Scheme 14).  
 
 
Scheme 14: Use of sulfonamides in the preparation of sulfoximines mediated by 
Pb(OAc)4.36 
 
   The subsequent work on the imination of sulfoxides using sulfonamides has been 
performed by Bolm. In 2004, various N-R sulfoximines were prepared in moderate to 
excellent yields by the reaction of R-NH2 and sulfoxides catalyzed by [Rh2(OAc)4] 
(Scheme 15).37 Furthermore, optically active sulfoximines were obtained when 
enantiomerically enriched sulfoxides were used as reactants. 
 
 
Scheme 15: Use of amides in the preparation of sulfoximines catalyzed by 
[Rh2(OAc)4].37 
 
In 2005, a metal-free imination of sulfoxides was achieved with a combination of 
NsNH2 and PhI(OAc)2 (Scheme 16).38 A variety of N-Ns sulfoximines were formed in 
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good yields. 
 
Scheme 16: Use of sulfonamides in the preparation of sulfoximines without 
metal catalyst.38 
  
In 2006, an iron-catalyzed imination of sulfoxides was reported using Fe(acac)2 
as catalyst to prepare sulfoximines in moderate to excellent yields by Bolm (Scheme 
17).39 The enantiomerically enriched sulfoximines were obtained when optically 
active sulfoxides were used as reactants. 
 
 
Scheme 17: The iron-catalyzed imination of sulfoxides using sulfonamides as the 
nitrene source.39 
     
    Metal-catalyzed or metal-free iminations of sulfoxides by using sulfonamides as 
the nitrene source are popular due to high yields, mild reaction conditions, 
stereoselectivities and a broad range of substrates. 
1.2.1.2.4 Use of iminoiodinanes (Ph-I=N-X) 
In 1998, the iminoiodinane Ph-I=N-Ts was reported as the nitrene source for the 
imination of sulfoxides catalyzed by CuOTf (Scheme 18).40 Various N-Ts 
sulfoximines were produced in good to excellent yields. Enantiomerically enriched 
sulfoximines resulted using optically active sulfoxides as reactants. 
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Scheme 18: Use of Ph-I=N-Ts in the imination of sulfoxides.40 
 
The combination of Ph-I=N-Ts and soluble copper (II) salts proved to be efficient 
in the imination of sulfoxides by Malacria and co-workers.41 Various N-Ms 
sulfoximines were synthesized using Ph-I=N-Ms as the nitrene source according to 
this protocol.42 Other similar iminoiodane reagents, like Ph-I=N-Ns (4-nitrophenyl 
sulfonyl) or Ph-I=N-Ses (trimethylsilylethyl sulfonyl), were also applied in this 
method by Tye and co-workers.43 Unfortunately, the results were unsatisfactory. In 
2007, various metal catalysts have been investigated for this protocol by Bolm.44 
[Rh2(OAc)4], AgNO3/t-But-Py and Fe(acac)2 proved to be efficient in the imination of 
sulfoxides, while copper and iron catalysts gave the best results when the substrate 
contained heteroatoms. 
1.2.2 Sulfilimines as intermediates 
1.2.2.1 The oxidative imination of sulfides 
1.2.2.1.1 The enantioselective imination of sulfides 
Only limited methods have been reported for the enantioselective imination of 
sulfides to sulfilimines. In 1996, the enantioselective imination of sulfides was 
achieved by Uemura and co-workers using the reaction of sulfides and Ph-I=NTs in 
the presence of CuOTf catalyst and chiral 4,4'-disubstituted bis(oxazoline) ligands 
(Scheme 19).45-47 Unfortunately, the ee values were unsatisfactory.  
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Scheme 19: Use of the combination of CuOTf and chiral 4,4'-disubstituted 
bis(oxazoline) ligands in enantioselective imination of sulfides.45 
 
Since 1999, a series of metal-Salen catalysts has been used in enantioselective 
sulfimidation as reported by Katsuki and co-workers.48,49  
 
 
Scheme 20: Use of Mn (III)-Salen in the enantioselective sulfimidation.48 
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The Mn (III)-Salen catalysts 32 were first reported and the complex 32a (R = 
-(CH2)4- , X = PF6 ) proved to be the best one (Scheme 20).48 Compared to the 
catalysis systems reported before, the ee values were improved significantly when the 
Mn(Ⅲ)-Salen was used as catalyst. When the (OC)Ru(II)-Salen 33 was used (Figure 
3),49 both the yields (ranging from 93 to 99%) and ee values (ranging from 81% to 
99%) had been improved greatly to excellent, except for S-benzyl-S-methyl sulfide. 
Due to the difficulties in the preparation of the Salens, the application of metal-Salens 
in enantioselective sulfimidation of sulfides is rare 
 
 Figure 3: (OC)Ru(II)-Salen which was used in the enantioselective sulfimidation of 
sulfides.49 
 
The Fe(Ⅲ )-bis(oxazolinyl)pyridine or bis(oxazoline) ligands were used in 
enantioselective sulfimidations of sulfides in combination with iron salts by Bolm.50 
Various metal salts were tested, and iron(III) 4-chloro-2,6-dimethyl-3,5-heptane 
dionate [Fe(dmhdCl)3, 34] proved to be best. Bis(oxazoline) pyridines and 
bis(oxazoline)s were tested as ligands, and (R,R)-2,6-bis(4-phenyl-2-oxazolinyl) 
pyridine [(R,R)-Ph-PyBOX, 35] gave the best er values (Scheme 21). The 
iron-catalyzed asymmetric imination of sulfides with ligand 35 gave satisfying yields 
and er values. 
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Scheme 21: The iron-catalyzed asymmetric imination of sulfides.50 
1.2.2.1.2 The preparation of N-CN sulfilimines  
Due to their bioactivity,51 the preparation of N-cyano sulfilimines and 
sulfoximines have been extensively studied. In 1972, Swern and co-workers prepared 
the tetracovalent sulfur compounds by treating sulfides with t-BuOCl at low 
temperature (-50 oC to -60 oC).52 The corresponding N-CN sulfilimines were obtained 
in moderate yields by the reaction of this tetracovalent compounds and NaNHCN 
(Scheme 22). In 1979, the desired N-CN sulfilimine was prepared in 75% yield in the 
presence of PhI(OAc)2 and NH2CN by Closier and co-workers.53 
 
 
Scheme 22: The preparation of N-CN sulfilimines by treating sulfides with 
t-BuOCl and NH2CN.52 
 
In 2007, various N-CN sulfilimines were prepared by Bolm using a combination 
of NBS and t-BuOK.54,55 Due to the low cost of the reagents, the simple procedure, a 
wide substrate scope and good to excellent yields, this protocol is useful (Scheme 23).  
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Scheme 23: Use of a combination of NBS and t-BuOK for the preparation of 
N-CN sulfilimines.54 
 
The oxidation of N-CN sulfilimines with m-chloroperoxybenzoic acid (m-CPBA) 
was used to prepare the corresponding N-CN sulfoximines. Furthermore, the N-H 
sulfoximines were accessed by removal of cyano group with trifluoroacetic anhydride 
(TFAA) in CH2Cl2, and subsequent with K2CO3 in methanol54 or under acidic 
conditions.55 Moreover, a variety of N-(1H)-tetrazole sulfoximines have been obtained 
by the reaction of N-CN sulfoximines and NaN3 in moderate to excellent yields 
(Scheme 24).56 
 
 
Scheme 24: The preparation of N-(1H)-tetrazole sulfoximines from N-CN 
sulfoximines.56 
 
Additionally, N-CN sulfoximines were also considered to be synthesized by the 
reaction of BrCN and N-H sulfoximines in the presence of a strong base.57 
Unfortunately, the toxicity of BrCN limited the application of this protocol. 
1.2.2.2 The oxidation of sulfilimines 
   Sulfilimines are known to be oxidized by m-chloroperoxybenzoic acid 
(m-CPBA),58,59 H2O2,60 NaOCl61 and other oxidants to afford the corresponding 
sulfoximines.   
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1.3 The preparation of sulfonimidoyl derivatives 
1.3.1 Sulfonimidoyl halides 
Due to the importance of sulfonimidoyl chlorides in the synthesis of their 
derivatives, such as sulfonimidoyl fluorides,62 sulfonimidamides,63 sulfoximines64,65 
and other sulfonimidoyl derivatives,66 the efficient preparations of sulfonimidoyl 
chlorides are crucial.  
Initially, sulfonimidoyl chlorides were prepared by the reaction of sulfinyl 
chlorides and chloroamine-T by Levchenko and co-workers.67 The application of this 
protocol was limited due to the instability of sulfonimidoyl chlorides to this reaction 
conditions. In 1971, sulfonimidoyl chlorides were prepared by oxidative chlorination 
of the corresponding sulfonamides with chlorine by Johnson and co-workers (Scheme 
25).63 Unfortunately, the products decomposed easily in the presence of the 
by-product, HCl. Moreover, due to the toxicity and the hard to handle character of 
chlorine, the application of this protocol was limited. 
 
 
Scheme 25: The preparation of sulfonimidoyl chlorides using Cl2.63 
 
In 1979, another oxidant, t-BuOCl, was used in the preparation of sulfonimidoyl 
chlorides.64 Due to the simple procedure and easy purification of products, t-BuOCl 
has been widely used in the preparation of sulfonimidoyl chlorides. 
In 1993, sulfonimidoyl halides (including Br and Cl) were also accessed by the 
reaction of N-TMS sulfonamides and dihalophosphoranes by Roy (Scheme 26).68 
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Scheme 26: The preparation of sulfonimidoyl halides from N-TMS sulfonamides 
and dihalophosphoranes.68 
 
In 2011, sulfonimidoyl fluorides were prepared using sulfonimidoyl chlorides as 
reactants by Bolm (Scheme 27).62  
 
  
Scheme 27: The preparation of sulfonimidoyl fluorides from sulfonimidoyl 
chlorides.62a 
 
The fluorination of sulfonimidoyl chlorides with a combination of KF and 
18-crown-6 or AgF was achieved to afford the corresponding sulfonimidoyl fluorides 
in good yields. Various phenyl and alkyl sulfonimidoyl fluorides were synthesized. 
Furthermore, the trifluoromethylation of sulfonimidoyl fluorides was completed in the 
presence of Bu4NF (TBAF) and TMSCF3 to afford various S-CF3 sulfoximines in 
moderate to good yields (Scheme 28).62a  
 
Scheme 28: The preparation of S-CF3 sulfoximines.62a 
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1.3.2 Sulfonimidates 
In contrast to the reaction of alcohols and sulfonimidoyl chlorides,64,68,69 
sulfonimidates were also synthesized in low yields using N-TMS sulfonamides and 
dichlorotriarylphosphoranes as reactants in the presence of 2,2,2-trifluoroethanol and 
Et3N (Scheme 29).68  
 
 
Scheme 29: The preparation of a sulfonimidate from a N-TMS sulfonamide.68 
 
   In 2002, a new method for the preparation of sulfonimidates using iodosobenzene, 
alcohols and sulfonamides in CH3CN at room temperature was reported by Malacria 
and co-worker (Scheme 30).70  
 
 
Scheme 30: The preparation of sulfonimidates in the presence of iodosobenzene, 
alcohols and sulfonamides.70 
 
A variety of sulfonimidates were obtained in moderate to excellent yields from 
the corresponding sulfonamides in a mild one-pot procedure. In 2006, a combination 
of diacetoxyiodosobenzene and the mild base MgO was introduced in the preparation 
of N-Ar sulfonimidates from N-Ar sulfonamides.71 
1.3.3 Sulfonimidamides 
Due to the wide application in asymmetric catalysis72,73 and in medicinal 
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chemistry,74 sulfonimidamides became increasingly attractive. Commonly, 
sulfonimidamides were prepared using sulfonimidoyl chlorides as reactants.63,68,69 In 
2007,  sulfonimidamides were synthesized from sulfonamides directly by Bolm 
(Scheme 31).75 In this work, a range of halogenating reagents (including 
chloramine-T, I2, NBS, NCS, t-BuOCl and bromamine-T), amines and solvents were 
screened. Finally, NCS proved to be the optimal halogenating reagent and CH3CN 
was the best solvent. In this manner, various sulfonimidamides were obtained in 
excellent yields. 
 
R S
O
NHPG R S
O
N
N
halogenating reagent
amide, solvent, r.t.
PG
R1
R2
40 50
Yields: 53-94%  
Scheme 31: The preparation of sulfonimidamides from sulfonamides.75 
1.4 The functionalization of sulfoximines. 
As various applications for sulfoximines exist (see chapter 5), it is attractive to 
broaden the library of sulfoximines by their further functionalization. As shown in 
Figure 4, there are several addressable positions in N-H aryl alkyl sulfoximines. 
Significant work has been done for the N- and α-functionalization. Research 
concerning the sulfonimidoyl group as directing group for the 
ortho-functionalizations is underway.  
 
 
 
Figure 4: Active positions of N-H aryl alkyl sulfoximines. 
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1.4.1 α- Functionalization 
1.4.1.1 α-Halogenation 
In 1978, an α-halogenation of N-protected sulfoximines with t-BuOCl at 0 oC in 
the presence of K2CO3 was reported by Johnson and co-workers (Scheme 32).76 
Various α-halo sulfoximines were obtained in moderate to good yields from the 
N-protected sulfoximines, no matter if the R was electron-rich or electron-poor 
(Scheme 32, Eq. 1). Furthermore, N-chloro-S-(chloroalkyl)-S-phenyl sulfoximines 
were obtained by using N-H sulfoximines as reactants (Scheme 32, Eq. 2). 
 
 
Scheme 32: Halogenation of different sulfoximines.76 
1.4.1.2 α-Lithiation 
The α-position of sulfoximines is known to be activated by the 
electron-deficiency of the sulfonimidoyl group. Hence, the α-H of sulfoximines can 
be removed by strong bases like n-BuLi to form nucleophiles. Subsequently, 
β-hydroxy sulfoximines were obtained upon treatment this nucleophile with 
aldehydes or ketones followed by dehydration in the presence of strong acid to form 
S-vinyl sulfoximine derivatives (Scheme 33).77 A variety of applications of S-vinyl 
sulfoximines in synthesis have been investigated.78-80 
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Scheme 33: The preparation and functionalization of α-lithiated sulfoximines.77 
1.4.1.3 α-Arylation  
In 2002, an intramolecular α-arylation of N-H sulfoximines was reported by 
Bolm.81 The heterocycles 61 were formed in good yields by the reaction of N-H 
sulfoximines and dibromoarenes catalyzed by a Pd complex in combination with 
rac-BINAP and t-BuONa (Scheme 34).  
 
 
Scheme 34: The intramolecular α-arylation of N-H sulfoximines.81 
 
In 2005, the intermolecular α-arylation of N-protected sulfoximines with aryl 
halides was reported by the same group.82 A variety of phenyl benzyl sulfoximine 
derivatives were prepared by the reaction of aryl bromides and N-benzoyl 
sulfoximines ethyl esters using Pd/Phosphorus ligand catalysis in the presence of 
t-BuONa (Scheme 35). The corresponding N-H sulfoximines 66 were obtained by 
saponification and decarboxylation of N-Bz sulfoximines with NaOH solution, 
followed by deprotection of N-Bz sulfoximine 65 with a BH3-THF complex. 
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Scheme 35: The preparation of α-arylated sulfoximines and phenyl benzyl 
sulfoximine derivatives.82 
1.4.2 N-Functionalization 
1.4.2.1 N-Nitrification 
Commonly, N-nitrification of N-H sulfoximines are accessed according to the 
protocol reported by Winternitz and Mutti in 1986.83 Various N-nitro sulfoximines 
were synthesized in good to excellent yields by treating N-H sulfoximines with 
concentrated HNO3 in DCM at 0-10 oC and subsequently Ac2O in combination with a 
catalyst amount of 93% aqueous H2SO4 solution in DCM at 20-50 oC (Scheme 36). 
 
 
Scheme 36: The preparation of N-nitro sulfoximines.83 
1.4.2.2 N-Halogenation 
N-Chlorinations and N-brominations of N-H sulfoximines can take place easily in 
the presence of halogenating reagents. Due to their special reactivity,84,85 the 
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application of N-halo sulfoximines is synthetically interesting. 
1.4.2.2.1 N-Bromination 
   Initially, N-bromo sulfoximines were prepared from Br2 and N-H sulfoximines 
according to a procedure reported by Appel and co-workers.86 Later, NBS was used as 
brominating reagent87 instead of Br2 (Scheme 37). 
 
 
Scheme 37: The N-bromination of N-H sulfoximines with NBS.87 
1.4.2.2.2 N-Chlorination 
Chlorinating reagents for N-chlorinations of N-H sulfoximines include NaOCl29, 
t-BuOCl76, Cl288 or NCS89. Now, t-BuOCl and NCS are commonly used for 
N-chlorinations of N-H sulfoximines due to the simple procedure. 
1.4.2.3 N-Acylation 
Generally, N-acylations of N-H sulfoximines can be achieved using acyl halides 
or anhydrides according to the approach reported by Bolm.90,91 The N-acylated 
sulfoximines were produced in excellent yields by treating N-H sulfoximines with 
acyl halides (acyl chlorides and acyl bromides) or anhydrides in the presence of a base 
(such as NEt3, pyriding or t-BuOK) in CH2Cl2 at 0 oC (Scheme 38). No epimerization 
was observed in N-acylation of optically active N-H sulfoximines. 
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Scheme 38: The N-acylations of N-H sulfoximines with acyl halides.90 
 
A carbodiimide-mediated (DCC or EDC-mediated) coupling of N-H 
sulfoximines with carboxylic acids was introduced in the preparation of N-acylated 
sulfoximines.90 The products were obtained in satisfacting yields even when bulky 
R-substituted carboxylic acids were used as reactants (Scheme 39). Similarly, the 
reaction was stereospecific. 
 
 
Scheme 39: The N-acylation of N-H sulfoximines from carboxylic acids.90 
     
Later, various N-acylated S-perfluoroalkylated sulfoximines were prepared in 
good to excellent yields in the presence of acyl chlorides, chloroformates, carbamoyl 
chlorides, chlorothionoformates and thiocarbamoyl chlorides by Magnier (Scheme 
40).92  
 
 
Scheme 40: The preparation of N-acylated S-perfluoroalkylated sulfoximines.92 
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In 2011, the N-acylation of N-H sulfoximines with carboxylic acids mediated by 
boric acid was reported by Harmata (Scheme 41).93 The desired products were formed 
in moderate to good yields for the alkyl carboxylic acids. In contrast, no desired 
products were detected when aromatic carboxylic acids were used. 
 
Scheme 41: The N-acylation of N-H sulfoximines mediated by a boric acid.93 
 
In 2013, the oxidative cross-coupling reaction of N-H sulfoximines with 
aldehydes catalyzed by CuBr in combination with t-butyl hydroperoxide (TBHP) was 
introduced in the preparation of N-acylated sulfoximines by Bolm (Scheme 42).94 
Various products were obtained in good to excellent yields independent of the use of 
aryl or alkyl aldehydes. 
 
 
Scheme 42: The preparation of N-acylated sulfoximines by using the oxidative 
cross-coupling reaction.94 
1.4.2.4 N-Alkylation 
Due to the low nucleophilicity of the sulfoximine nitrogen, limited methods for 
the preparation of N-alkylated sulfoximines have been reported. In 1968, Johnson and 
co-worker prepared the N-methylated and N-ethylated sulfoximines by treating N-H 
sulfoximines with strong electrophilic trialkyloxoniumn salts or olefins in a 
combination with NaH (Scheme 43).95 
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Scheme 43: The N-alkylation of N-H sulfoximines using strong electrophilic 
trialkyloxoniumn salts or olefins in a combination with NaH.95 
 
This protocol has suffered from the limitation of the trialkyloxoniumn salts and 
the electrophilic olefins. As an improvement, the N-methylation of N-H sulfoximines 
with a combination of aq. formaldehyde solution and formic acid was reported by 
Cram and co-workers.96 N-Methylated sulfoximines were obtained under 
Eschweiler-Clark reaction conditions (Scheme 44). 
 
 
Scheme 44: The preparation of N-methylated sulfoximines under Eschweiler-Clark 
reaction conditions.96 
 
A variety of alkyl halides and alkyl sulfonates were introduced in the 
N-alkylation of N-H sulfoximines by Johnson and Lavergne (Scheme 45).97a Various 
products were obtained in good to excellent yields using alkyl bromides as alkylating 
reagents in the presence of KH and a catalytic amount of a phase transfer catalysts 
(PTC) such as tetrabutylammonium bromide, benzyltriethylammonium chloride or 
tributylhexadecylphophonium bromide in 1,2-dimethoxyethane (DME). In 2014, the 
N-alkylation of N-H sulfoximines using alkyl bromides with KOH in DMSO at room 
temperature has been developed to prepare N-alkylated sulfoximines in good to 
excellent yields (up to 97%) by the Bolm group.97b   
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Scheme 45: The N-alkylations of N-H sulfoximines using alkyl halides and alkyl 
sulfonates as alkylating reagents.97a 
 
Other alkylating reagents, such as alkyl chlorides, iodides and sulfonates (OTs 
and OMs), were investigated as alternatives to bromides. Except for alkyl iodide, 
satisfying results were obtained in all cases. Moreover, varioius solvents and bases 
were screened. DME and KH proved to be best. 
In 2002, N-alkylated sulfoximines were prepared from N-acylated sulfoximines 
by Bolm.91 A variety of N-alkylated sulfoximines were obtained in good yields using 
N-acylation of N-H sulfoximine and subsequent borane reduction under mild 
conditions. The process was determined to be stereospecific (Scheme 46). 
 
 
Scheme 46: The preparation of N-alkylated sulfoximines from N-acylated 
sulfoximines.91 
1.4.2.5 N-Alkenylation 
Compared to other N-functionalizations, methods for the synthesis of 
N-alkenylated sulfoximines are rather limited. The first N-alkenylation of N-H 
sulfoximine was reported by Bolm in 2004 (Scheme 47).98  
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Scheme 47: The preparation of N-alkenylated sulfoximines by a palladium-catalyzed 
process.98 
 
A variety of N-vinyl sulfoximines were obtained in excellent yields by 
palladium-catalyzed coupling of N-H sulfoximines with vinyl bromides or vinyl 
triflates in the presence of BINAP and t-BuONa at 110 oC under argon. The N-vinyl 
sulfoximines are easily reduced with hydrogen under palladium-catalysis to form 
N-alkylated sulfoximines in moderate yields, providing a new method for the 
preparation of N-alkylated sulfoximines. Subsequently, a copper-catalyzed coupling 
of N-H sulfoximines with vinyl bromides was achieved.99 
In 2005, other unsaturated sulfoximines, namely 1,2-benzoisothiazoles, were 
prepared by the reaction of S-2-bromophenyl-S-methylsulfoximine and various 
terminal alkynes.100 The major products 88 were obtained in moderate yields with a 
combination of palladium catalysts , CuI and Et3N in DMF (Scheme 48).  
 
 
Scheme 48: The preparation of 1,2-benzoisothiazoles with palladium catalysts.100 
1.4.2.6 N-Alkynylation  
The first N-alkynylation of sulfoximines has been reported by Bolm in 2013.101 
The N-alkynylated sulfoximines were formed in good yields by copper-catalyzed 
oxidative cross coupling of N-H sulfoximines with terminal alkynes (Scheme 49). It 
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is worth mentioning that the N-alkynylated sulfoximines are prone to hydrolyze to 
form the corresponding N-acylated sulfoximines during column chromatography on 
silica gel. 
 
 
Scheme 49: The copper-catalyzed oxidative cross-coupling of N-H sulfoximines 
with terminal alkynes.101 
 
The N-alknylation of N-H sulfoximines by copper-catalyzed oxidative 
decarboxylative coupling with aryl propiolic acids was reported by Bolm in the same 
year (Scheme 50).102 A variety of desired products were obtained in good to excellent 
yields under mild conditions with a simple procedure. 
 
 
Scheme 50: The N-alknylation of sulfoximines by copper-catalyzed oxidative 
decarboxylative coupling.102 
 
N-Alknylated sulfoximines are potential intermediates in organic synthesis, which 
has been used to react with ketenes affording sulfoximine cyclobutenones in excellent 
yields according to a [2+2]-cycloaddition process.103 Correspondingly, a 
(Z)-N-alkenylated sulfoximine was obtained in good yield by a palladium-catalyzed 
hydrogenation (Pd/C).102 
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1.4.2.7 N-Arylation 
N-Aryl sulfoximines are normally formed by using aryl nitrene reagents.104 
However, they can also be obtained easily by transition metal-catalyzed cross 
coupling of N-H sulfoximines with aryl halides. Most of the pioneering works in this 
field stems from Bolm and Harmata. 
1.4.2.7.1 Use of aryl bromides and aryl iodides 
In 1998, N-arylations of sulfoximines by palladium-catalyzed cross coupling of 
N-H sulfoximines with aryl bromides in the presence of chelating bisphosphines 
(BINAP or Tol-BINAP) and  Cs2CO3 in toluene was reported by Bolm and 
co-workers (Scheme 51).105 Various products were synthesized in good to excellent 
yields. In 1999, a broader substrate scope for this method was investigated by the 
same group. Aryl iodides proved to be also available in this protocol.106 
 
 
Scheme 51: The N-arylation of sulfoximines by palladium-catalyzed cross 
coupling of N-H sulfoximines with aryl bromides.105 
 
In 2005, copper salts were used for N-arylations of sulfoximines by Bolm.107 
N-aryl sulfoximines were produced by the reaction of N-H sulfoximine and aryl 
halides (bromides or iodides) in a combination with CuI and Cs2CO3 or CsOAc in 
DMSO at 90 oC (Scheme 52). Compared to the palladium-catalyzed cross coupling, 
the copper methodology was advantageous, due to shorter reaction time and ligand 
free catalysis. 
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Scheme 52: The preparation of N-aryl sulfoximines by the copper methodology.107 
 
In 2008, an iron-catalyzed cross-coupling of N-H sulfoximines with aryl iodides 
was reported by Bolm (Scheme 53).108 Various N-aryl sulfoximines were formed in 
good to excellent yields in the presence of inexpensive FeCl3, 
N,N’-dimethylethylenediamine (DMEDA) and K2CO3 in toluene under argon. Due to 
the advantages of iron as a catalyst mentioned before, the iron methodology was a 
good complement. The use of aryl bromides was investigated in this study as well. 
Unfortunately, the yields were low (about 10%). 
 
 
Scheme 53: The iron-catalyzed cross-coupling of N-H sulfoximines with aryl 
iodides.108 
1.4.2.7.2 Use of aryl chlorides 
In 2004, aryl chlorides were used as arylating agents in the N-arylation of N-H 
sulfoximines by Harmata.109 The desired products were obtained in good yields by 
microwave-assisted N-arylations of N-H sulfoximines with aryl chlorides (Scheme 
54). Furthermore, a new methodology using the reaction of N-H sulfoximines with 
aryl dichlorides was investigated.110 
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Scheme 54: The microwave-assisted N-arylation of N-H sulfoximines with aryl 
chlorides.109 
 
In 2011, an efficient catalyst system of Pd2(dba)3 and RuPhos 97 (Figure 5) was 
reported for the N-arylation of N-H sulfoximines.111 Good yields (ranging from 60% 
to 90%) were obtained by the reaction of N-H sulfoximines and aryl chlorides in the 
presence of Pd2(dba)3, RuPhos and Cs2CO3 in toluene at 135 oC. Aryl bromides 
proved to be also effective in this catalyst system. 
 
 
Figure 5: RuPhos. 
1.4.2.7.3 Use of aryl nonaflates, aryl triflates and aryl sulfonates 
Besides aryl halides, aromatic compounds substituted by appropriate leaving 
groups, such as aryl sulfonates (Ts), aryl triflates (Tf) and aryl nonaflates (Nf), were 
also investigated in N-arylations of N-H sulfoximines.112 In the presence of Pd(OAc)2, 
BINAP and Cs2CO3, various N-aryl sulfoximines were obtained in good to excellent 
yields using aryl triflates and aryl nonaflates as arylating reagents. Moreover, when 
aryl sulfonates were used as reactants, various products were accessed in moderate 
yields using a Ni(cod)2/BINAP catalyst system (Scheme 55). 
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Scheme 55: The N-arylation of N-H sulfoximines with aryl triflates and aryl 
nonaflates.112 
1.4.2.7.4 Use of aryl boronic acids 
In 2005, copper-catalyzed N-arylations of N-H sulfoximines with aryl boronic 
acids were achieved under mild conditions by Bolm.113 Various N-aryl sulfoximines 
were produced in good to excellent yields by using copper salts as catalysts in the 
absence of ligands and base in MeOH at room temperature (Scheme 56). Cu(OAc)2 
proved to be the most effective. 
 
 
Scheme 56: The copper-catalyzed N-arylation of N-H sulfoximines with aryl boronic 
acids.113 
1.4.2.7.5 Use of diaryliodonium salts 
In 2012, diaryliodonium salts was introduced in the N-arylation of N-H 
sulfoximines by Varma and co-worker.114 Various N-aryl sulfoximines were obtained 
in good to excellent yields catalyzed by CuBr in the presence of a presaturated 
solution of aqueous PEG-400 at room temperature under sonication for 5 min 
(Scheme 57). Due to the simple procedure, this method is a good complement to the 
N-arylation of N-H sulfoximines. 
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Scheme 57: The N-arylation of sulfoximines with diaryliodonium salts.114 
1.4.3 Sulfonimidoyl group as directing group for the 
ortho-functionalization 
In 2013, the first report on the sulfonimidoyl group as directing group for the 
ortho-CH-functionalization of sulfoximines was reported by Bolm.115 
1,2-Benzothiazines were firstly prepared by rhodium-catalyzed cross coupling of N-H 
sulfoximines with alkynes in good yields (Scheme 58).  
 
 
Scheme 58: The rhodium-catalyzed cross coupling of N-H sulfoximines with alkynes 
to form 1,2-benzothiazines.115 
 
As a consequence, the ortho-olefination of N-protected sulfoximines catalyzed 
by rhodium complexes was developed.116 N-Acyl and N-aryl sulfoximines were used 
as reactants, and the olefinations selectively occurred at the ortho-position of S-phenyl 
sulfoximines catalyzed by a combination of [Cp*RhCl2]2, AgSbF6 and Cu(OAc)2  
H2O to afford the desired products in moderate to excellent yields (Scheme 59). 
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Scheme 59: The rhodium-catalyzed ortho-olefination of N-protected sulfoximines.116 
1.5 The application of sulfoximines 
1.5.1 As ligands 
Sulfoximines attracted increasing interest of chemists and biologists since 
decades. For instance, the application of sulfoximines as ligands in asymmetric 
catalysis has been developed. To date, sulfoximines were used as ligands in the 
enantioselective addition of aldehydes,117,118 the asymmetric allylic alkylation,119-122 
the asymmetric hydrogenation,123-125 the enantioselective halogenation126 and the 
asymmetric vinylogous Mukaiyama aldol reactions.127 
1.5.2 As chiral auxiliaries 
Sulfoximines were also applied as chiral auxiliaries in organic synthesis. They 
were used to control the stereochemistry in the formation of asymmetric centers on 
multi-membered rings,128 asymmetric d3-synthons129 and functionalized asymmetric 
azaheterocycles130,131. The pioneering work on the benzothiazines (Figure 6) as chiral 
auxiliaries in asymmetric organic syntheses has been performed by the group of 
Harmata.132-134 
 
 
Firgure 6: The structure of benzothiazines. 
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1.5.3 As bioactive compounds 
Since methionine sulfoximine was found to be bioactive,1 the sulfoximines were 
applied gradually in medicinal chemistry.135 A few examples are presented below. 
1.5.3.1 Sulfoximine-based Vioxx® analogues 
In 2011, sulfoximine-based Vioxx® analogues 109 were designed and 
synthesized by Bolm ( Figure 7).136 Compared to sulfone Vioxx® (108), 
sulfoximine-based Vioxx® analogues 109 showed a moderate COX-2 selectivity and 
lower hERG (the human Ether-à-go-go-Related Gene) blocking potencies (Figure 7). 
Interestingly, N-CN sulfoximines showed anticancer activity and COX inhibition 
while the mutagenicity and cellular toxicity were low.51 
 
 
Figure 7: The sulfone- and sulfoximine-based Vioxx® analogues. 
1.5.3.2 Sulfoximine-based HIV-1 protease inhibitors 
A variety of sulfoximine-based pseudosymmetric HIV-1 (Human 
Immunodeficiency Virus) protease inhibitors such as compound 110 and 111 (Figure 
8) have been found.137-139 The free hydroxy group of HIV-1 protease inhibitors is 
considered to be important for the interaction with the catalytic aspartic acids. The 
tetrahedral structure of sulfoximines and their potential hydrogen-bond 
donor/acceptor function made them favorable candidates for a “transition state 
mimic” (TSM) in HIV-1 protease inhibition. 
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Figure 8: Sulfoximine-based pseudosymmetric HIV-1 protease inhibitors. 
1.5.3.3 Sulfoximine-based inhibitors of carboxypeptidase A 
Sulfoximine-based transition-state analogue 112 of the carboxypeptidase A 
(CPA) was designed and synthesized by Mock and Tsay (Figure 9).140 Subsequently, 
a modification towards 113 was achieved by Kim (Figure 9).141 Both 
sulfoximine-based CPA inhibitors efficiently blocked carboxypeptidase A. 
 
 
Figure 9: Sulfoximine-based inhibitor of carboxypeptidase A. 
1.5.3.4 Sulfoximine-based calcitriol analogues 
   Due to the important role of calcitriol in the antiproliferative and growth 
regulatory effects of normal and neoplastic cells, selective and low-calcemic 
inhibitors of the CYP24 hydroxylase are attractive. A sulfoximine-based CYP24 
hydroxylase inhibitor 114 was designed and synthesized by Posner (Figure 10).142  
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Figure 10: Sulfoximine-based CYP24 hydroxylase inhibitor. 
1.5.3.5 Sulfoximine-based inhibitors of cyclin-dependent kinases 
Due to the possible use of cyclin-dependent kinases (CDKs) in treatment of 
cancer, CDKs inhibitors have attracted increasing attention. The sulfoximine-based 
CDKs inhibitors 115 and 116 (Figure 11) were designed, synthesized and tested in 
treatment of cancer by Lücking and co-workers.143,144 The compound 116 proved to 
be a potent candidate for the treatment of cancer according to the test results. Further 
investigation are underway. 
 
Figure 11: Sulfoximine-based inhibitors of cyclin-dependent kinases. 
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2 Research Plan 
(1) Bioactive sulfilimine or sulfoximine-based compounds 
This thesis mainly focusses on the further investigation of the bioactivity of 
sulfoximines. Inspired by the corresponding sulfones already known to possess 
biological activity, the bioactivities of sulfoximine-based compounds are expected to 
differ significantly. Accordingly, novel sulfilimine and sulfoximine analogs will be 
designed, synthesized and tested regarding their potential bioactivity. 
 
 
 
Compared to the known sulfone, the biological properties of sulfilimine or 
sulfoximine-based compounds were changed significantly after a O/N-exchange. And 
further investigation of the variation was underway. 
 
(2)The N-alknylation of N-H sulfoximines 
Due to their numerous applications exisiting in various fields, this work aims to 
expand the library of sulfoximines in general. In this context, novel methodologies for 
the N-functionalization should be investigated, especially for the N-alknylation. Thus, 
the thesis will also focus on the search for a new method for the N-alknylation of N-H 
sulfoximines. 
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3 Results and discussion 
3.1 Bioactive sulfoximines 
3.1.1 Bioactive sulfoximine-based acyclic triaryl olefins 
3.1.1.1 Background 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the 
treatment of inflammatory diseases. The cyclooxygenases COX-1 and COX-2 are 
found to be the key enzyme in this treatment. According to comprehensive studies,145 
selective COX-2 inhibitors (COXIBs) are considered as potent anti-inflammatory 
agents. In addition, COXIBs are attractive in the treatment of breast cancer due to the 
role of COX-2-derived PGE2 in breast tumor initiation and progression.146 A general 
structure including two or more aromatic substituents linked by a conjugated core 
with a para-sulfonyl or sulfonimidoyl group connected to one of the arenes proved 
beneficial for the selectivity of COX-2 activity (Figure 12). 51,136,147 
 
 
Figure 12: The general structure beneficial for the selectivity of COX-2 
inhibitory activity. 
 
In 2004, a new class of highly potent and selective sulfone-based COX-2 
inhibitors 117 with an acyclic triaryl olefinic structure was designed, synthesized and 
tested (Figure 13 ).147,148 
 
Results and discussion 
41 
 
 
Figure 13: The sulfone-based triaryl olefinic COX-2 inhibitors. 
 
Along those inhibitors, compound 117c exhibited the highest potency [with a 
maximum COX-2 potency (IC50 = 0.014 μM)] and best COX-2 selectivity [selectivity 
index (SI) > 7142]. In contrast, compound 117g does neither inhibit COX-1 or 
COX-2. 
In our previous work on sulfoximine-based Vioxx® analogs, the O/N-exchange, 
leading from a sulfone to the corresponding sulfoximine, was found to be beneficial 
for reduced hERG inhibitory activity.51,136 Hence, we were interested in the 
bioactivities of the corresponding sulfoximines of sulfone-based triaryl olefins 117. 
To obtain more information, the sulfoximine-based acyclic triaryl olefins 118 and 119 
(Figure 14) were designed, synthesized and tested. In this context, COX-1 and 
COX-2 inhibitory activities and blocking potencies of both estrogen receptors ERα 
and ERβ were investigated. 
 
 
Figure 14: The sulfoximine-based acyclic triaryl olefinic inhibitors. 
3.1.1.2 Synthesis 
The sulfoximine-based acyclic triaryl olefins 118 and 119 were prepared 
following Knaus’ procedure147,148 and methods developed in our laboratories54,56 
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(Scheme 60). Starting with ketone 120 and benzophenone (121), compound 122 was 
obtained in 86% yield. The subsequent metal-free imination of compound 122 with a 
combination of NH2CN and PhI(OAc)2 afforded N-cyano sulfilimine 123 in 80% 
yield. Then, N-cyano sulfoximine 124 was obtained in 75% yield by oxidation of 
N-cyano sulfilimine 123 with m-CPBA and K2CO3. The removal of cyano group was 
achieved by treating N-cyano sulfoximine 124 with 50% H2SO4 to form N-H 
sulfoximine 118b in 88% yield.149 Finally, the N-methylation of sulfoximine 118b 
was accessed under the Eschweiler-Clark reaction conditions, which led to N-methyl 
sulfoximine 119b in 66% yield (Scheme 60).95  
 
 
Scheme 60: Synthesis of sulfilimine- and sulfoximine-based inhibitors. 
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3.1.1.3 COX inhibition 
Due to the extraordinary COX-2 selectivity of sulfonyl-substituted triaryl olefin 
117, especially 117c (COX-1: IC50 >100 μM; COX-2: IC50 = 0.014 μM) reported by 
Knaus and co-workers, the COX inhibitions of compounds 118, 123 and 124 were 
tested (Table 1). To our disappointment, none of the synthesized compounds showed 
a mojor COX inhibition. 
 
Table 1: COX inhibition. 
entry structure Inhibition (%) at 10μM 
COX-1 COX-2 
1 7 7 
2 5 10 
3 12 17 
 
Following the docking studies by Knaus,147 the double hydrogen-bonds between 
the two oxygens of the sulfonyl moiety and the NH of Phe518, the NH2 of Arg513 in the 
COX-2 active site are essential for COX-2 inhibition. However, the tethered cyano 
groups of sulfilimine 123 and sulfoximine 124 lead to a weakening of those 
hydrogen-bonds resulting in almost complete inactivity towards COX inhibition. 
Results and discussion 
44 
 
Compared to sulfone 117, the hydrogen-bonds should be improved after an 
O/N-exchange because of the existence of the better H-bond acceptor nitrogen atom 
in the sulfoximine moiety. However, the COX inhibition data indicate the opposite. A 
possible reason could be that the NH of the sulfoximine moiety does not act as H- 
acceptor but as H-donor. 
3.1.1.4 The estrogen binding affinities 
Because sulfoximine-based bioactive compounds are considered to be used in 
cancer treatments, especially breast cancer,143,144 the estrogen binding affinities 
(including ERα and ERβ) of sulfone-based 117c and sulfoximine-based 118, 123 and 
124 were evaluated. The results are summarized in Table 2. 
 
Table 2: The estrogen binding affinities. 
entry structure Inhibition (%) at 10μM 
ERα ERβ 
1 
 
83 72 
2 
 
54 60 
3 
 
91 80 
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entry structure  Inhibition (%) at 10μM 
ERα ERβ 
4 -6 77 
 
To our delight, sulfone 117c was a selective ERβ agent (entry 4). Sulfilimine 123, 
sulfoximines 118b and 124 showed moderate to high blocking potencies for both 
estrogen receptors without a significant ERα/β selectivity (entries 1–3). Compared to 
N-H sulfoximine 118a, which shown moderate activities with 77% and 53% 
inhibition for ERα and ERβ, respectively, N-H sulfoximine 118b showed better 
activities with 91% and 80% inhibition for ERα and ERβ, respectively. In addition, 
N-cyano sulfoximine 124 showed moderate activities for both ERα (54%) and ERβ 
(60%) as well. To our surprise, N-cyano sulfilimine 123 also exhibited good activities 
for both ERα (83%) and ERβ (72%).  
Considering the results of sulfone-based triaryl olefinic COX-2 inhibitors 117, 
the replacement of the sulfonyl moiety by a sulfoximidoyl moiety showed a major 
impact on the bioactivities. Sulfone-based analogue 117c is not only a selective 
COX-2 inhibitor but also a selective ERβ binder. Sulfoximine 118 showed almost no 
COX inhibition but better estrogen receptor inhibition with a lack of ERα/β selectivity 
when compared to analogue 117c. Without docking studies of sulfone 117 and 
sulfoximines on estrogen receptors, conclusions for the binding of affinities on 
molecular level and potential molecule alignments in the binding sites of ERα and 
ERβ are difficult to give. 
3.1.1.5 Conclusion 
New sulfoximine-based acyclic triaryl olefins have been designed and 
synthesized. The inhibitory effects against COX as well as binding affinities to both 
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estrogen receptors have been investigated. Compared to the results obtained in the 
studies of sulfonyl-substituted analogues 117, the sulfonimidoyl group showed a 
major impact on the COX inhibition and estrogen receptor binding. In contrast to the 
sulfone-based analog 117c which is a selective COX-2 inhibitor and selective for ERβ, 
all sulfilimine-based and sulfoximine-based analogues showed low COX inhibition. 
However, good binding to both estrogen receptors were observed. Among sulfilimine 
and sulfoximine-based analogues, sulfoximine 118b showed remarkable inhibitions 
for ERα and ERβ of 91 and 80%, respectively. In following studies, more 
sulfoximine-based compounds should be prepared.  
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3.1.2 Sulfoximine- and sulfilimine-based Dapsone analogues 
3.1.2.1 Background 
Due to the interest in dye properties of simple diaryl sulfones, 
4,4’-diaminodiphenyl sulfone 9 (Dapsone) was synthesized by Fromm and Wittmann 
in 1908 (Figure 15).150 
 
 
Figure 15: Structure of 4,4’-diaminodiphenyl sulfone (9, Dapsone). 
 
In 1937, dapsone was tested for the first time towards its anti-inflammatory 
potencies against induced infections in mice by Buttle151 and Fourneau152. Since then, 
dapsone has been in clinical use for the treatment of various infections and chronic 
inflammatory diseases, especially in dermatology.153 Dapsone proved to be useful for 
the treatment of mutibacillary and paucibacillary leprosy and a variety of neutrophilic, 
eosinophilic, and autoimmune dermatoses in combination with other antibiotic 
agents.154 Due to the adverse effects including hematologic, nerveous system and 
gastrointestinal/hepatic effects,155 dapsone variants exhibiting the positive therapeutic 
properties of the original drug without the unwanted side effects are desirable. In view 
of the results of COX-blocking properties of sulfoximines,51,136,156 the biological 
impact induced by O/N-exchange at the central sulfonyl core of dapsone has been 
investigated.  
Herein, the new sulfoximine- and sulfilimine-based dapsone analogues 125 and 
126 (Figure 16) were synthesized and tested. 
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Figure 16: Sulfoximine- and sulfilimine-based dapsone analogues. 
3.1.2.2 Synthesis of sulfoximine-based analogue 126 
The desired analogues were prepared using a combination of known 
procedures157-162 and methods developed in our laboratories.54,56 The preparation of 
sulfoximine-based dapsone analogue 126 is shown in Scheme 61. 
 
 
Scheme 61: The synthesis of sulfoximine-based dapsone. 
Results and discussion 
49 
 
Bis(4-nitrophenyl)sulfane (129) was obtained in 79% yield by heating the 
mixture of 1-bromo-4-nitro benzene (127), Na2S and S8 in DMF/H2O. The reduction 
of the nitro groups of bis(4-nitrophenyl) sulfane (129) with the combination of iron 
powder and a catalytic amount of conc. HCl in EtOH afforded 4,4'-diaminodiphenyl 
sulfide (130) in 83% yield. N,N’-[4,4’-thiobis(4,1-phenylene)] diacetamide (131) was 
obtained in 64% yield by acetyl protection of the two amino groups of sulfide 130. 
Metal-free imination of compound 131 using cyanamide gave N-cyano sulfilimine 
132 in 47% yield. N-cyano sulfoximine 133 was obtained in 78% yield after oxidation 
of 132 with a combination of m-CPBA and K2CO3 in ethanol. The corresponding N-H 
sulfoximine 126 was obtained in 85% yield by simultaneous removal of the cyano 
group and the two acetyl groups of N-cyano sulfoximine 133 with a combination of 
conc. HCl and ethanol. 
A metal-free imination of bis(4-nitrophenyl)sulfane (129) using a combination of 
PhI(OAc)2 and NH2CN was trialled to afford correspondingly N-cyano sulfoximine 
directly. Unfortunately, no product was formed. Probably the electron-withdrawing 
properties of the NO2 groups on the benzene ring are unfavorable for this imination. 
For that reason, the reduction of nitro groups had to be completed first. Due to their 
sensitivities towards oxidation, the amino groups needed to be protected before the 
imination. Initially, the Boc group was used as a protecting group because of its easy 
removal, but the resulting sulfide with the two amino groups protected by Boc was 
instable to the imination conditions. The use of acetyl protecting groups led to several 
disadvantages, such as a low solubility of N,N’-[4,4’-thiobis(4,1-phenylene)] 
diacetamide (131) in common organic solvents and the instablity of cyano group 
towards the conditions required for the deprotection of acetyl groups. Therefore, the 
sequence had to be improved by using alternative effective amino protecting groups. 
3.1.2.3 Synthesis of sulfoximine-based analogue 125 
The N-cyano sulfilimine-based dapsone analogue 125 was prepared according to 
the route shown in Scheme 62.  
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Scheme 62: The synthesis of sulfilimine-based analog 125. 
 
Because of the mild removal conditions and the stability of the phthalic group, 
isobenzofuran-1,3-dione was used to protect the amino groups of 4,4'-
diaminodiphenyl sulfide (130) to afford compound 135 in 79% yield. Then, N-cyano 
sulfilimine was formed by metal-free imination of compound 135 with NH2CN and 
PhI(OAc)2. After a simple work-up, cleavage of the phthalic protecting groups by 
treatment with aqueous hydrazine monohydrate (60% aq.) and ethanol, N-cyano 
sulfilimine 125 was obtained in 32% yield over two steps. The cyano group proved to 
be stable under these basic conditions. 
The disadvantages of the phthalic group as protecting group include the low 
solubility of compound 135 and instability under the imination conditions. 
3.1.2.4 The biological properties of sulfilimine 125 and 
sulfoximine 126 
The COX inhibitions of compounds 125 and 126 were tested, and the results are 
depicted in Table 3. To our disappointment, both sulfilimine 125 and sulfoximine 126 
were inactive at 10 μM concentrations. 
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Table 3: COX inhibition. 
entry structure Inhibition (%) at 10μM 
COX-1 COX-2 
1 9 4 
2 
 
6 4 
  
In a next test, the leukotriene (LTB; LTB4) and tumor necrose factor (TNF; 
non-selective) of the two dapsone analogues 125 and 126 were evaluated (Table 4).  
 Neither sulfilimine-based analog 125 nor sulfoximine-based analog 126 showed  
significant binding potencies for LTB4 or TNF. The evaluation of other biological 
properties of sulfoximine-based and sulfilimine-based dapsone analogues should be 
performed in the future. 
 
Table 4: LTB4 and TNF. 
entry structure Inhibition (%) at 10μM 
LTB4 TNF 
1 11 -3 
2 
 
-14 -6 
3.1.2.5 Conclusion 
The new dapsone variants sulfilimine 125 and sulfoximine 126 were prepared 
and their biological properties were evaluated. Neither sulfilimine-based analogue 125 
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nor sulfoximine-based analogue 126 showed COX inhibition or binding to LTB4 and 
TNF. Apparently, the minor change (O/N-exchange) on the sulfonyl core of 
compound 6 has a major influence on its biological properties. More information 
regarding the impact induced by O/N-exchange should be studied by preparing more 
sulfoximine-based analogues on the basis of similar sulfone-based biological 
inhibitors. 
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3.1.3 The potentially bioactive sulfonimidoyl fluorides 
3.1.3.1 Phenylmethyl sulfonimidoyl fluorides 
3.1.3.1.1 Background 
Phenylmethyl sulfonyl fluoride 136 (PMSF, Figure 17) is known as an inhibitor 
of serine protease (including trypsin, chymotrypsin, thrombin and papain) which is 
commonly used in the preparation of cell lysates.163,164  
 
 
Figure 17: Phenylmethyl sulfonyl fluoride (PMSF). 
 
Besides the above mentioned properties, PMSF also acts as inhibitor of the 
neutral chromatin protease,165 esterases such as acetylcholinesterase,163 and 
biosynthetic enzymes in the aromatic complex of neurospora166. By testing its 
analgesic and toxic properties on rats and mices using intraperitoneal (IP) injection, 
PMSF was found to be a potential parenteral analgesic in animals and humans.167,168 
However, PMSF has to be stored as solution in ethanol, methanol or isopropyl alcohol 
due to its instablity in aqueous media before use.169 
Since the wide application of PMSF in biochemistry, the preparation of new 
PMSF analogues is attractive.  
 
Figure 18: Sulfoximine-based PMSF analogues. 
 
Hence, the preparation of sulfoximine-based PMSF analogues 137 (Figure 18) is 
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described herein. 
3.1.3.1.2 Synthesis  
According to literature-known procedures,64,170 the desired sulfoximine-based 
PMSF analogues were synthesized as shown in Scheme 63. 
 
 
Scheme 63: Synthesis of sulfoximine-based PMSF analogues. 
 
The oxidative chlorination of phenylmethanethiol (138) with sulfuryl chloride 
and acetic acid afforded phenylmethyl sulfinyl chloride (139). After removal of the 
volatile compounds under vacuum, phenylmethyl sulfinyl chloride (139) was 
dissolved in dry ether and used directly in the next step. N-Methyl and N-benzyl 
benzyl sulfonamide (140a and 140b) were formed by the ammoniation of 
phenylmethyl sulfinyl chloride with 40% aqueous methylamine or benzylamine in 
ether in 78% yield and 42% yield, respectively. N-Methyl and N-benzyl 
phenylmethanesulfonimidoyl chloride (141a and 141b) were obtained after oxidative 
chlorination of the corresponding phenylmethane sulfonamides (140a and 140b) with 
t-BuOCl in DCM at 0 oC. The fluorination of sulfonimidoyl chloride (141) with AgF 
gave N-methyl phenylmethanesulfonimidoyl fluoride 137a in 45% yield and N-benzyl 
phenylmethanesulfonimidoyl fluoride 137b in 49% yield. N-Methyl 
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phenylmethanesulfonimidoyl fluoride 137a was also formed in 8% yield by using a 
combination of KF and a catalytic amount of 18-crown-6 as fluorinating reagent. The 
yield was increased to 21% when the amount of 18-crown-6 was raised to 1.5 
equivalents. 
According to the routes described below, N-H phenylmethanesulfonimidoyl 
fluoride and N-cyano phenylmethanesulfonimidoyl fluoride were attempted to be 
prepared (Scheme 64 and Scheme 65). Unfortunately, these attempts all failed. 
 
Scheme 64: The attempts to prepare N-H phenylmethanesulfonimidoyl fluoride 142. 
 
N-H Phenylmethanesulfonimidoyl fluoride 142 was tried to be accessed by 
removal of the benzyl protecting group of N-benzyl phenylmethanesulfonimidoyl 
fluoride by hydrogenation over Pd on carbon (10%) (Scheme 64, Eq. 1). To our 
disappointment, the desired product was not detected. Phenylmethane sulfonamide 
143 was obtained in 48% yield by treating phenylmethyl sulfinyl chloride 139 with 
25% aq. NH3 in ether. The NH2 group was Boc protected to give N-Boc 
phenylmethane sulfonamide (144). Access to N-Boc phenylmethanesulfonimidoyl 
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fluoride was envisaged from N-Boc phenylmethane sulfonamide (144). Unfortunately, 
oxidative chlorination of sulfonamide (144) with t-BuOCl, and subsequent 
fluorination with a combination of KF and 18-crown-6 failed to give the anticipated 
N-Boc sulfonimidoyl fluoride (145) (Scheme 64, Eq. 2). 
Due to the potential biological activity, the preparation of N-cyano 
phenylmethanesulfonimidoyl fluoride is also attractive.51 For its synthesis, the 
preparation of N-cyano phenylmethane sulfonamide was regarded as key step. 
Initially, the synthesis of N-cyano phenylmethane sulfonamide was attempted 
according to the routes shown in Scheme 65. 
 
 Scheme 65: The attempts to prepare N-CN phenylmethanesulfonimidoyl fluoride. 
 
The synthesis of N-cyano phenylmethane sulfonamide (146) was attempted by 
treatment of phenylmethyl sulfinyl chloride (139) with cyanamide using a similar 
procedure as above (Scheme 65). However, product 146 was not detected. Also the 
use of the more reactive NaNHCN remained unsuccessful in preparing N-cyano 
phenylmethane sulfonamide (Scheme 65, Eq. 1). Finally, the preparation of N-cyano 
phenylmethane sulfonamide (146) was changed in favor of the reaction of 
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phenylmethane sulfonamide (143) and BrCN in the presence of NaH (Scheme 65, Eq. 
2). Unfortunately, this attempt also failed. 
3.1.3.1.3 Further evaluation 
In future studies, the preparation of N-H and N-cyano 
phenylmethanesulfonimidoyl fluoride should be attempted and their biological 
activities should be invesigated. 
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3.1.3.2 Sulfonimidoyl fluoride inhibitors of the fatty acid amide 
hydrolase 
3.1.3.2.1 Background 
The fatty acid amide hydrolase is one of the integral membrane enzymes that 
regulates the degradation and inactivation of fatty acid amides in vitro. 
N-Acylethanolamines 147,171,172 N-acyltaurines 148173,174 and oleamide 149175 are 
three important categories of the fatty amines in vivo (Figure 19).  
 
R3 NH2
O
R1 N
H
OH
O
147 N-Acylethanolamine 149 Oleamide
R2 N
H
SO3
O
148 N-Acyltaurine  
Figure 19: Three important categories fatty acid amines. 
 
Since physiological effects induced by the fatty acid amide family in vivo 
involve neuroprotection,176 analgesia,177 sleep-inducing effects175 and modulation of 
the memory system,178 the control of the concentration of functional fatty acid amides 
in vivo is significant. Potent and selective fatty acid amide hydrolase inhibitors are the 
most effective tools to cure diseases induced by the lack of a certain fatty acid amides. 
The new fatty acid amide hydrolase (FAAH) inhibitors with good selectivity and high 
efficiency are demanded.  
In 2012, a variety of phenylalkyl sulfonyl fluorides 150 were synthesized and 
investigated towards their biological properties as fatty acid amide hydrolase 
inhibitors by Makriyannis (Figure 20).179  
 
 
Scheme 20: The FAAH inhibitors based on sulfonyl fluorides. 
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Various fatty acid amide hydrolase inhibitors, such as 5-(4-hydroxyphenyl) 
pentanesulfonyl fluoride and 5-(4-benzyloxyphenyl)pentanesulfonyl fluoride, 
especially 5-(4-hydroxyphenyl)pentanesulfonyl fluoride, exhibited good inhibition of 
the fatty acid amide hydrolase. Particularly, 5-(4-hydroxyphenyl) pentanesulfonyl 
fluoride exhibited a similar enzyme inhibition in both rats and humans.179  
Inquiring the biological properties of similar sulfoximine-based FAAH inhibitors, 
N-methyl phenylpentanesulfonimidoyl fluorides 151 (Figure 21) were designed and 
synthesized. 
 
 
Figure 21: The sulfoximine-based FAAH inhibitors. 
3.1.3.2.2 Synthesis 
The first synthetic challenge in the synthesis was the formation of the 
phenylpentane moiety. According to the procedure reported by Makriyannis,179 the 
phenylpentane moiety was formed by olefination from phosphonium bromides, 
followed by a subsequent reduction of the corresponding alkenes with Pd/C (Scheme 
66). 
 
 
Scheme 66: The formation of the phenylpentane moiety by Makriyannis.179 
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Here, the formation of the phenylpentane moiety was modified and the details 
are shown in Scheme 67. It was obtained in 43% yield by treating 
1-(benzyloxy)-4-bromobenzene (159) with n-BuLi, followed by 
1,5-dibromopentane.180 Then, S-{5-[4-(benzyloxy)phenyl]pentyl} ethanethioate (161) 
was obtained in 72% yield by the reaction of 1-(benzyloxy)-4-(5-bromopentyl) 
benzene (160) and AcSH in the presence of K2CO3 and a catalytic amount of KI. N-
Methyl benzenepentanesulfinamide (162) was formed in 93% yield by oxidative 
chlorination of S-{5-[4-(benzyloxy)phenyl]pentyl} ethanethioate (161) with a 
combination of SO2Cl2 and AcOH at -10 oC for 30 min, and subsequently treatment 
with a 40% aq. solution of CH3NH2.170  
 
 
Scheme 67: Synthesis of sulfonimidoyl fluoride. 
 
The oxidative chlorination of N-methyl benzenepentane sulfinamide (162) with 
t-BuOCl in CH2Cl2, and the subsequent fluorination with AgF in CH3CN, afforded 
N-methyl phenylpentanesulfonimidoyl fluoride (151a) in 50% yield. Before using 
AgF as the fluorinating reagent, KF was used for the fluorination combined with 18- 
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crown-6 (ranging from catalytic amounts to 1.5 equiv.) to give the product in an 
unsatisfying yield of less than 10%. The removal of benzyl group is still under 
investigation. 
3.1.3.2.3 Further work 
The formation of N-methyl-5-(4-hydroxyphenyl)pentane sulfonimidoyl fluoride 
151b has yet to be completed. The biological activity of sulfoximine-based fatty acid 
amide hydrolase inhibitors will then be tested. More studies about the 
sulfoximine-based potential inhibitors should be evaluated and the variation of 
bioactivity should be studied. More potent and selective sulfoximine-based fatty acid 
amide hydrolase inhibitors should be designed and prepared. 
3.1.3.3 Conclusion 
The sulfoximine-based potentially bioactive compounds 137 and compound 
151a have been synthesized. The syntheses of sulfonimidoyl fluoride 151b and N-H 
phenylpentanesulfonimidoyl fluoride are under investigation. The biological activities 
of sulfonimidoyl fluorides will be evaluated. The effect on the bioactivities induced 
by the O/N–exchange will be screened. 
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3.2 N-Alkynylation of N-H sulfoximines with bromo 
acetylenes 
3.2.1 Background 
Sulfoximines have been used as ligands in asymmetric synthesis,117-127 applied as 
chiral auxiliaries in organic syntheses128-134 and studied as bioactive candidates in 
medicine and crop science.135-144 To find the new synthetic pathways of sulfoximines 
appeared highly desirable. Considerable efforts have been made to functionalize 
sulfoximines, and various N-functionalizations, such as N-nitrification,83 
N-halogenation,29,76,84-89 N-acylation,90-93 N-arylation,104-114 N-alkylation,94-97 
N-alkenylation98-100 and N-alkkynylation101,102, have been introduced.  
Due to the potential of sequential functionalizations (Scheme 68),102,103,181 the 
N-alkynyl sulfoximines attracted our interest. As of yet, only two methods (and an 
incorrect, disproven example)182,183 have been described for the preparation of 
N-alkynyl sulfoximines (Scheme 69).101,102  
 
 
Scheme 68: Sequential functionalizations of N-alkynyl sulfoximines. 
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Scheme 69: The two methods of the preparation of N-alkynyl sulfoximines.101,102 
 
To overcome the limitation of the methods reported, new methods for the 
N-alkynylation of sulfoximines were desirable. Inspired by the preparation of 
ynamides by the reaction between N-R2 sulfonamides and 1-bromo-1-alkyne in the 
presence of a copper catalyst (Scheme 70, Eq. 1),184 a reaction between N-H 
sulfoximines and bromoacetylenes was attempted for the preparation of N-alkynyl 
sulfoximines. To our delight, the N-alkynyl sulfoximines were obtained under similar 
conditions (Scheme 70, Eq. 2). 
 
 
 
Scheme 70: The preparation of ynamides and yne sulfoximines. 
3.2.2 Screening of the reaction conditions  
Inspired by the preparation of ynamides using sulfonamides and 
bromoacetylenes,184-187 the N-alkynylation of N-H sulfoximines was trialled using 
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(bromoethynyl)benzene and racemic S-methyl-S-phenyl sulfoximine under standard 
conditions as reported. The desired product was obtained in 64% yield after 24 hours 
at 60 oC under argon. Then, several conditions were investigated. Due to the 
instability of N-alkynyl sulfoximines,101 the reaction mixture was passed through a 
pad of Celite 545 and washed with acetone/Et3N = 50/1. Finally, the volatiles were 
removed under reduced pressure. The desired product was obtained after column 
chromatography on basic Al2O3 or deactivated basic Al2O3 (Deactivated basic Al2O3 
was prepared by adding 10 mLof water to 200 mLof activated basic Al2O3). 
3.2.2.1 Copper catalysts 
To investigate the effect of the copper catalyst, various copper salts were applied 
under the standard reaction conditions. The results are shown in Table 5.  
 
Table 5: The effect of different copper salts. 
 
Entry Copper catalyst Yield (%)
1 CuSO4•5H2O 64 
2 CuSO4 58 
3 Cu(OAc)2•H2O 60 
4 Cu(OAc)2 68 
5 CuCl2 65 
6 CuI 67 
 
All copper salts trialled were effective in promoting the reaction. The desired 
product was obtained in moderate yield independent of the oxidation state and the 
counterion (entries 1-5). The reaction proved to be insensitive to water and the anions 
in the copper salts. Finally, Cu(OAc)2 was chosen as catalyst for further investigation 
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(entry 4). 
3.2.2.2 Bases 
    Next, the effectivity of various bases was investigated to the reaction. Carbonates, 
phosphate, acetate, alcoholate, hydroxide and pyridine were trialled, and the results 
are shown in Table 6. 
 
Table 6: The effect of different bases. 
 
Entry Base Yield (%) 
1 K2CO3 68 
2 Na2CO3 8 
3 Cs2CO3 6 
4 KOAc 0 
5 K3PO4 30 
6 t-BuOK 2 
7 KOH 5 
8 pyridine 51 
 
Potassium carbonate was found to be the most effective base affording the desired 
product in 68% yield (entry 1). Applying other carbonates resulted only in traces of 
product (6-8%, entries 2 and 3). Using potassium phosphate, acetate, t-butanolate and 
hydroxide resulted in low yields (entries 1 and 4-7). When 2.5 equivalent of pyridine 
was applied as base, the desired product was obtained in 51% yield. According to 
these results, the basicity of base seems to be crucial for the reaction. The highest 
yield was obtained when potassium carbonate was used as base.  
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3.2.2.3 Reaction temperature 
    The temperature of the reaction was investigated, and the results are shown in 
Table 7.  
 
Table 7: The effect of temperature. 
 
Entry Temperature (oC) Yield (%)
1 40 40 
2 60 68 
3 80 48 
 
    At 60 oC, the highest yield for this process was achieved (68%, entry 2). Raising 
the temperature to 80 oC or lowering it to 40 oC both led to a reduced yield (entries 1 
and 3). Hence, 60 oC was chosen as optimal temperature for the reaction. 
3.2.2.4 The ligands 
Besides 1,10-phenanthroline (20 mol%), pyridine (20 mol%) was also trialled as 
ligand for the reaction yielding 31% of the desired product (Table 8). 
 
Table 8: The effect of 
ligands
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Entry Ligand (20 mol%) Yield (%) 
1 1,10-phenanthroline 68 
2 pyridine 31 
 
3.2.2.5 Reaction time 
   The reaction time was varied to optimize the yield. The results are shown in Table 
9.  
 
Table 9: The effect of reaction time. 
 
 
Entry Time (h) Yield (%) 
1 24 68 
2 48 72 
3 72 74 
 
The yield was slightly increased when the reaction time was prolonged from 24 
hours to 48 hours or 72 hours. Finally, 48 hours was chosen as the reaction time (entry 
2). 
3.2.2.6 The ratio of the substrates 
In order to investigate the influence of the ratio of both substrates, the ratio of 
(bromoethynyl)benzene and racemic S-methyl-S-phenyl sulfoximine was varied from 
1.5/1 to 1/1.5 and the yield of 90a was observed. The results are shown in Table 10. 
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Table 10: The effect of the ratio of reactants. 
 
 
Entry x / y  Yield (%) 
1 1.5 / 1 60 
2 1 / 1 67 
3 1 / 1.2 72 
4 1 / 1.5 73 
 
These investigations showed that the yield decreased when excessive 
(bromoethynyl)benzene was used (entry 1-2). In contrast, using an excess of 
S-methyl-S-phenyl sulfoximine, the yield increased (entries 1-3). When more than 1.2 
equiv. of sulfoximine was applied, no additional beneficial effect was observed, and 
the yield was almost unchanged (entries 2-3). 
3.2.2.7 Solvents 
To screen the effect of the solvent, various solvents were trialled. The results are 
shown in Table 11.  
 
Table 11: The effect of different solvents. 
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Entry Solvent Yield (%) 
1 toluene 72 
2 DCE 50 
3 1,4-dioxane 55 
4 DMF 8 
 
The results indicate that the yield decreased when the polarity of solvents was 
increased. DMF, as the most polar solvent, resulted in the lowest yield (8%, entry 4). 
Compared to toluene, DCE and 1,4-dioxane gave similar yields (entries 2-3). Thus, 
polar solvents proved to be adverse in this reaction. 
3.2.2.8 Reaction atmosphere 
When the reaction was performed under air instead of argon, the desired product 
was obtained in 62% yield which is only a slight decrease compared to the regular 
conditions. The details are shown in Table 12.  
 
Table 12: The effect of atmosphere. 
 
 
Entry Atmosphere Yield (%) 
1 argon 72 
2 air 62 
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3.2.2.9 The optimal conditions 
The conditions used for all following reactions were identified as 1.2 equiv. of 
the sulfoximine, 1 equiv. of bromoacetylene, 10 mol% of Cu(OAc)2, 20 mol% of 1,
10-phenanthroline, 2.5 equiv. of K2CO3, toluene, 60 oC, 48 h and argon. 
3.2.3 Scope of bromoacetylenes 
With the optimal conditions in hand, the substrate scope for bromoacetylenes 
was investigated. A variety of bromoacetylenes including aryl bromoacetylenes with a 
diverse substitution pattern, alkenyl bromoacetylenes, silyl bromoacetylenes and alkyl 
bromoacetylenes were screened towards their reactivity with S-methyl-S-phenyl 
sulfoximine under the optimal conditions. The results are shown in Table 13. 
 
Table 13: Scope of bromoacetylenes. 
 
 
Entry Product  Yield (%) 
   
1 
 
 
72 
2 
 
71 
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Entry Product  Yield (%) 
3 
 
34 
4 
 
86 
5 
 
82 
6 
 
43 
7 
 
74 
8 
 
0 
9 
 
81 
10 
 
85 
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Entry Product  Yield (%) 
11 
 
62 
12 
 
71 
13 
 
46 
14 
 
61 
15 
 
24 
16 0 
 
As shown in Table 13, various para-substituted (bromoethynyl)benzenes were 
used as substrates (entries 2-6), and para-halogenated (bromoethynyl)benzenes 
performed best to afford the desired products in the highest yields of 86% for 90d and 
82% for 90e, respectively (entries 4-5). The presence of para-halo substitution of 
benzene ring maybe result the polarization of triple bonds of products 90d and 90e in 
a favorable range, which lead to higher yields (entries 4-5). The yields decreased 
when the para-position was substituted by an electron-donating methoxy group or 
electron-withdrawing nitro group, 34% for 90c and 43% for 90f, respectively (entries 
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3 and 6). One reason for the low yields of compounds 90c and 90f may be their 
instability. Compared to the products 90d and 90e, the polarization of the triple bond 
of products 90c and 90f were changed. The details could be observed in the 13C-NMR 
spectrum (Figure 21). For product 90c, the polarization of the triple bond was 
insufficient, and the polarization of the triple bond was too high for 90f. It is worth 
mentioning that the cross-coupling happened selectively between the carbon of the 
triple bond and the nitrogen of the sulfonimidoyl moiety for 
para-halo-4-(bromoethynyl)benzene. The desired N-alkynyl sulfoximines with a 
para-halogen could be functionalized at the halogen position and yielded further 
attractive sulfoximines. 
 
 
Figure 21: The polarization of the triple bond of products 90c, 90d and 90f.  
  
For different ortho-substituted (bromoethynyl)benzenes (entries 7-10), the 
desired products were obtained in good yields except for 
ortho-methoxy-4-(bromoethynyl)benzene (90h, entry 8). Product 90h was obtained 
together with the hydrolyzed by-product because of the instability of 90h. The reason 
for this instability may be an interaction between the oxygen atom at ortho-position 
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and the triple bond, which could activate the triple bond. 
ortho-Bromo-4-(bromoethynyl)benzene performed best to give product 90j in 85% 
yield because the hindrance of bromo in ortho-position maybe prevent the active 
agents to attack the triple bond. 
 For different meta-substituted (bromoethynyl)benzenes (entries 11-13), the 
desired products were obtained in moderate yields. meta-Chloro-4- 
(bromoethynyl)benzene gave product 90l in 71% yield which was lower than the 
yields obtained with para-chloro-4-(bromoethynyl)benzene and 
ortho-chloro-4-(bromoethynyl)benzene. In contrast, using meta-chloro-4-(bromo 
ethynyl)benzene afforded product 90k in 62% yield, which was higher than the yields 
given by para-methoxy-4-(bromoethynyl)benzene and ortho-methoxy 
-4-(bromoethynyl)benzene. The chemical shifts of the two carbons of triple bond in 
product 90k are 87.72 and 58.99 ppm, respectively, which are close to the product 
90d. The polarity of the triple bond potentially stabilized the product 90k. 
Furthermore, product 90k did not involve coordination between the oxygen and the 
triple bond, contrary to product 90h. 
(E)-(4-Bromobut-1-en-3-yn-1-yl)benzene, (bromoethynyl)triisopropylsilane and 
(bromoethynyl)cyclopropane were also applied in the reaction (entries 14-16). 
(Bromoethynyl)triisopropylsilane reacted with S-phenyl-S-methyl sulfoximine 
affording product 90n in 61% yield. It is interesting that the chemical shifts of the two 
carbons on triple bond in product 90n are 102.08 and 54.14 ppm, which means the 
polarization of triple bond in product 90n is much higher than the other products. 
Product 90n should be unstable if only the polarization is taken into consideration, 
which is contrary to the result. The coordinating bond between the silicon atom and 
the triple bond may be the reason for the good stability of product 90n.101 Due to the 
instability of both (E)-(4-bromobut-1-en-3-yn-1-yl)benzene and the corresponding 
product, 90o was obtained in only 24% yield. The product 90p was not stable enough 
towards column chromatography because of the  electron-donating effect of the 
cyclopropyl group.  
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3.2.5 Scope of sulfoximines 
Various sulfoximines, including diaryl sulfoximines, para-subsitituted phenyl 
methyl sulfoximine and phenyl alkyl sulfoximines, were investigated in the reaction. 
The results are shown in Table 14.  
 
Table 14: Scope of sulfoximines. 
 
 
Entry  Product  Yield (%) 
1 
 
82 
2 
 
47 
3 
 
64 
4 
 
71 
5 56 
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Entry  Product  Yield (%) 
6 54 
7 
 
26 
8 
 
0 
 
The yield decreased when the methyl group of S-methyl-S-phenyl sulfoximine 
was replaced by i-propyl, n-hexyl and phenyl group (entries 2-4). The presence of 
sterically demanding groups such as i-propyl resulted in the lowest yields (47% for 
90q, entry 2). Additional conjugation by a second phenyl group (entry 4) compensated 
the negative effect by the steric hindrance and product 90s was obtained in 71% yield. 
Even long saturated side-chain n-hexyl was tolerated well and the corresponding 
product 90r was obtained in moderate yield (64%, entry 3). When the para-position 
of S-methyl-S-phenyl sulfoximine was replaced by a bromo or a nitro group, the 
yields decreased (56% for 90t and 54% for 90u). The para electron-withdrawing 
groups on the aromatic ring seemed unfavorable for this reaction. Furthermore, the 
attempt to prepare product 90w failed. Due to the combined effects of the low 
solubility of S,S-methyl sulfxoximine in toluene, the low conjugation and steric 
hindrance of the ortho-bromo substituent, product 90v was obtained in only 26% 
yield. 
3.2.7 Conclusion 
The preparation of N-alkynylated sulfoximines using N-H sulfoximines and 
bromoacetylenes as substrates was achieved. A range of N-alkynylated sulfoximines 
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were obtained in the moderate to good yields under mild conditions with an 
inexpensive copper catalyst under basic conditions in toluene. The conditions and 
substrate scope were screened, and interesting results about the conditions and the 
starting materials were obtained. 
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4 Summary 
The work of this thesis was mainly focussed on the syntheses of bioactive 
compounds, especially sulfoximine-based potential bioactive compounds. Several 
new molecules have been synthesized and unprecedented synthetic pathways were 
investigated. The biological activities of the products were evaluated and initial 
studies of the effect induced by O/N-exchange of sulfoximine-based bioactive 
compounds were conducted.  
(1) Bioactive sulfoximine-based acyclic triaryl olefins 
 
 
 
The bioactive sulfoximine-based acyclic triaryl olefins were synthesized in a 
moderate overall yield. The biological activities were evaluated. Different from the 
sulfone-based acyclic triaryl olefins 117, the sulfoximine-based acyclic triaryl olefins 
were good binding to the estrogen receptors without ERα/β selectivity, and they 
showed no COX inhibition. 
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(2) Sulfoximine- and sulfilimine-based dapsone analogues 
 
 
 
The sulfoximine- and sulfilimine-based dapsone analogues were synthesized and 
their biological activities were evaluated. Neither the sulfoximine- nor the 
sulfilimine-based dapsone analogues showed COX inhibition, and both did not 
interact with LTB4 and TNF. The evaluation of other biological properties is 
underway. 
(3) Bioactive sulfonimidoyl fluorides 
 
 
 
The potentially bioactive sulfonimidoyl fluorides 137a/b and 151a were 
synthesized. In future studies, the preparation of the corresponding N-H sulfonimidoyl 
fluorides should be further investigated. Subsequently, the biological properties of 
these sulfonimidoyl fluorides should be evaluated. 
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(4) The N-alkynylation of N-H sulfoximines with bromoacetylenes 
 
 
 
A new methodology for the preparation of N-alkynylated sulfoximines using N-H 
sulfoximines and bromoacetylenes was developed. A broad range of N-alkynylated 
sulfoximines was obtained in good to excellent yields under mild conditions in the 
presence of inexpensive copper salts and a common base. 
 
  
 
Experimental part 
81 
 
5 Experimental part: 
5.1 General information 
Melting points were determined on a Büchi melting point B-540. 1H, 19F and 13C 
NMR spectra were recorded on a Varian Mercury 300, an Agilent VNMRS 400 or 
VNMRS 600 spectrometer in CDCl3, acetone-d6, DMSO-d6 and CD3OD at room 
temperature. Chemical shifts () are reported in parts per million (ppm), and TMS was 
used as internal standard when CDCl3 was used as solvent. A Thermo Scientific LTQ 
Orbitrap XL spectrometer was used for high-resolution mass spectrometry (HRMS), a 
Finnigan SSQ 7000 spectrometer was used for mass spectra, and an Elementar Vario 
EL instrument was used for elemental analyses. The infrared spectra (IR) were 
recorded on a Perkin-Elmer Spectrum 100 FT/IR using attenuated total reflection 
(ATR) or on a Perkin-Elmer FT/IR 1760 recorded as KBr pellets. 
All solvents (DCM, pentane, methanol, ethanol, ethyl acetate, diethyl ether and 
others) were distilled prior to use. Dry THF and dry toluene were distilled over 
solvona○R  under a nitrogen atmosphere. Other dry solvents were purchased from 
Acros.  
Important notices for the N-alkynylation of N-H sulfoximine: All 
sulfoximines56,188,189 and bromoacetylenes190,191 were prepared following literature 
procedures. All other chemicals were purchased from Acros, Alfa Aesar, ABCR 
Sigma-Aldrich or TCL, and used without further purification. 
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5.2 Procedures and product data  
5.2.1 Procedures and product data for the sulfoximine-based 
acyclic triaryl olefins 
S-[4-(1,1-Diphenylhex-1-en-2-yl)phenyl]-S-methyl sulfane (122)147,148 
 TiCl4 (9.44 mmol, 1 M in THF) was added dropwise to a stirred 
suspension of Zn (1.26 g, 19.2 mmol) in dry THF (20 mL) under 
argon at -10 oC, and the mixture was heated to reflux for 2 h, then 
cooled to 0 oC. A mixture of compound 120 (0.50 g, 2.4 mmol) 
and benzophenone (0.44 g, 2.4 mmol) in dry THF (48 mL) was added at 0 oC under 
argon, and the reaction mixture was heated to reflux for another 1.5 h. After cooling 
down to room temperature, the reaction mixture was poured into a 10% aq. K2CO3 
solution (80 mL). After vigorous stirring for 5 min, the dispersed insoluble material 
was removed by vacuum filtration with Celite 545. The organic layer was separated, 
and the aqueous layer was extracted with EtOAc (3 × 40 mL). The combined organic 
layers were dried over Na2SO4. The product was obtained as a white solid after 
column chromatography on silica gel using pentane/EtOAc = 100/1 as eluents. 1H 
NMR (600 MHz, CDCl3) δ = 7.38 (t, J = 7.6 Hz, 2H), 7.32–7.28 (m, 3H), 7.12–7.01 
(m, 7H), 6.97–6.94 (m, 2H), 2.50–2.44 (m, 5H), 1.38–1.23 (m, 4H), 0.84 (t, J = 7.3 
Hz, 3H); 13C NMR (150 MHz, CDCl3) δ = 143.6, 143.1, 140.4, 139.3, 139.2, 135.9, 
130.8, 130.1, 129.5, 128.2, 127.5, 126.6, 125.9, 125.8, 35.5, 31.2, 22.9, 15.7, 14.0. 
The spectroscopic data matched those reported in the literature. 
 
N-Cyano-S-[4-(1,1-diphenylhex-1-en-2-yl)phenyl]-S-methyl sulfilimine (123) 
Compound 123 was prepared according to a procedure reported 
in the literature.56 PhI(OAc)2 (354 mg, 1.1 mmol) was added to a 
solution of compound 122 (359 mg, 1 mmol) and NH2CN (63 mg, 
1.5 mmol) in CH3CN (20 mL), and the reaction mixture  was 
stirred at 0 oC. When the starting material was completely consumed (monitored by 
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TLC), the volatiles were removed under reduced pressure. The product was obtained 
as a white solid in 80% yield after column chromatography on silica gel using EtOAc 
as eluent. The melting point is 49.3–50.5 oC. 1H NMR (300 MHz, CDCl3) δ = 
7.54–7.45 (m, 2H), 7.33–7.13 (m, 7H), 7.00–6.91 (m, 3H), 6.83–6.74 (m, 2H), 2.90 (s, 
3H), 2.40 (t, J = 7.7 Hz, 2H), 1.29–1.08 (m, 4H), 0.72 (t, J = 7.0 Hz, 3H); 13C NMR 
(75 MHz, CDCl3) δ = 148.7, 142.7, 142.2, 141.7, 139.1, 133.5, 131.6, 130.7, 129.3, 
128.4, 127.9, 127.2, 126.6, 125.7, 120.6, 36.6, 35.5, 31.2, 22.9, 14.0; IR (ATR): υ = 
3020, 2928, 2862, 2148, 1739,1590, 1448,1374, 1156, 1079, 965, 837, 760, 699 cm-1; 
MS (EI), m/z (relative intensity) 398 [M]+ (2), 358 (100), 315 (14), 268 (40), 254 (10), 
237 (14), 205 (8), 191 (15), 178 (14), 167 (22), 149 (14), 137 (27), 122 (5), 91 (29); 
HRMS (ESI), m/z: [M+H]+ Calcd. for C26 H27N2S 399.1890, found 399.1886. 
 
N-Cyano-S-[4-(1,1-diphenylhex-1-en-2-yl)phenyl]-S-methyl sulfoximine (124) 
Compound 124 was prepared according to a procedure reported 
in the literature.56 K2CO3 (736 mg, 5.33 mmol) and 70% 
m-CPBA (656 mg, 2.66 mmol) were added to a stirred solution 
of compound 123 (705 mg, 1.77 mmol) in 20 mL of MeOH at 0 
oC, and the reaction mixture was stirred at room temperature until the starting material 
was completely consumed (about 30 min). After MeOH removed under reduced 
pressure, water was added. The resulting mixture was extracted with DCM (3 × 10 
mL), and the combined organic layers were dried over MgSO4. The product was 
obtained as a white solid in 75% yield after column chromatography on silica gel 
using pentane/EtOAc = 2/3 as eluents. The melting point is 121.7–123.5 oC. 1H NMR 
(400 MHz, CDCl3) δ = 7.72–7.65 (m, 2H), 7.37–7.13 (m, 7H), 7.04–6.89 (m, 3H), 
6.82–6.74 (m, 2H), 3.23 (s, 3H), 2.42 (t, J = 7.8 Hz, 2H), 1.44–1.08 (m, 4H), 0.73 (t, J 
= 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ = 151.3, 142.4, 142.4, 141.9, 138.8, 
133.2, 131.5, 130.7, 129.3, 128.4, 128.0, 127.5, 127.4, 126.9, 111.9, 45.0, 35.4, 31.2, 
22.9, 13.9. IR (KBr): υ = 3408, 3059, 2958, 2925, 2195, 1673, 1443, 1249, 1090, 967, 
825, 752, 701 cm-1; MS (EI), m/z (relative intensity) 414 [M]+ (100), 373 (31), 315 
(58), 267 (14), 167 (15), 91 (17); HRMS (ESI), m/z: [M+H]+ Calcd. for C26H27N2OS 
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415.1839, found 415.1843. 
 
S-[4-(1,1-Diphenylhex-1-en-2-yl)phenyl]-S-methyl sulfoximine (118b) 
Compound 118b was prepared according to a procedure reported 
in the literature.54 Compound 124 (124 mg, 0.3 mmol) was added 
to a 50% aq. H2SO4 solution (10 mL), and the reaction mixture 
was heated to 110 oC. The mixture was cooled to room 
temperature after the starting material was completely consumed (monitored by TLC), 
and neutralized by a 2 M aq. NaOH solution and a saturated aq. NaHCO3 solution, 
until the pH value was about 8. The resulting mixture was extracted with DCM (3 × 
10 mL), and the combined organic layers were dried over MgSO4. The product was 
obtained as a white solid in 88% yield after column chromatography on silica gel 
using pentane/EtOAc = 1/1 as eluents. The melting point is 122.6–123.8 oC. 1H NMR 
(400 MHz, CDCl3) δ = 7.75–7.65 (m, 2H), 7.34–7.13 (m, 7H), 7.01–6.90 (m, 3H), 
6.84–6.75 (m, 2H), 3.01 (s, 3H), 2.40 (t, J = 7.8 Hz, 2H), 1.45–1.09 (m, 4H), 0.72 (t, J 
= 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ = 148.4, 142.8, 142.3, 141.3, 140.9, 
139.5, 130.7, 130.6, 129.4, 128.4, 127.8, 127.4, 127.1, 126.5, 46.4, 35.6, 31.2, 22.9, 
14.0; IR (ATR): υ = 3178, 2953, 2859, 1590, 1491, 1214, 1090, 1000, 954, 835, 764, 
694 cm-1; MS (EI), m/z (relative intensity) 389 [M]+ (100), 374 (1), 346 (40), 282 (7), 
268 (16), 254 (6), 252 (19), 228 (3), 205 (10), 191 (25), 189 (12), 178 (11), 167 (23), 
91 (25); Anal. Calcd. for C25 H27NOS: C 77.08, H 6.99, N 3.60, Found: C 76.89, H 
7.158, N 3.52; HRMS (ESI), m/z: [M+H]+ Calcd. for C25H28NOS 390.1886, found 
390.1891. 
 
N-Mehtyl-S-[4-(1,1-diphenylhex-1-en-2-yl)phenyl]-S-methyl sulfoximine (119b) 
Compound 119b was prepared according to a procedure 
reported in the literature.95 Compound 118b (67 mg, 0.173 
mmol) and paraformaldehyde (52 mg, 1.73 mmol) were added 
to formic acid (10 mL), and the reaction mixture was heated to 
130 oC. After the starting material was completely consumed (about 3 days), the 
n-Bu
S
Me
O N H
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formic acid was removed under reduced pressure. Then, a 2 M aq. H2SO4 solution (10 
mL) was added, and the resulting mixture was extracted with DCM (3 × 10 mL). The 
combined organic layers were dried over MgSO4. The product was obtained as a 
white solid in 66% yield after column chromatography on silica gel using 
pentane/EtOAc = 1/1 as eluents. The melting point is 119.0–120.6 oC. 1H NMR (400 
MHz, CDCl3) δ = 7.63–7.55 (m, 2H), 7.33–7.12 (m, 7H), 6.98–6.88 (m, 3H), 
6.81–6.73 (m, 2H), 3.10 (s, 3H), 2.53 (s, 3H), 2.47 (t, J = 7.8 Hz, 2H), 1.30–1.10 (m, 
4H), 0.72 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ = 148.4, 142.8, 142.4, 
141.3, 139.7, 135.6, 130.9, 130.8, 129.4, 128.4, 128.4, 127.7, 127.1, 126.5, 44.7, 35.5, 
31.2, 29.5, 22.9, 14.0; IR (ATR): υ = 2959, 2920, 1737, 1585, 1447, 1237, 1145, 1084, 
968, 841, 765, 702 cm-1; MS (EI), m/z (relative intensity) 403 [M]+ (98), 359 (13), 
340 (100), 284 (24), 269 (9), 267 (11), 243 (11), 191 (15), 165 (14), 91 (9); Anal. 
Calcd. for C26 H29NOS: C 77.38, H 7.24, N 3.47, Found: C 77.03, H 7.252, N 3.40; 
HRMS (ESI), m/z: [M+H]+ Calcd. for C26H30NOS 404.2043, found 404.2042. 
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5.2.2 Procedures and product data for sulfoximine- and 
sulfilimine-based dapsone analogues 
Bis(4-nitrophenyl)sulfane (129)157,190 
A suspension of Na2S (2.93 g, 37.5 mmol) and S8 (1.2 g, 37.5 
mmol) in H2O/DMF (20 mL/10 mL) was added dropwise to a 
solution of 1-bromo-4-nitrobenzene (10.1 g, 50 mmol) in DMF (50 mL) at 110 oC, 
and the reaction mixture was stirred at 110 oC for 3 hours after the addition. After the 
suspension was cooled to room temperature, water was added until no more solid was 
formed. The product was obtained as a yellow solid in 79% yield after filtration and 
subsequent recrystallization from AcOH. 1H NMR (400 MHz, DMSO-d6) δ = 8.24 (d, 
J = 8.9 Hz, 4H), 7.63 (d, J = 8.9 Hz, 4H); 13C NMR (100 MHz, DMSO-d6) δ = 146.7, 
142.0, 131.3, 124.8. The spectroscopic data matched those reported in the literature. 
 
4-(4-Aminophenylthio)benzenamine (130)158,191 
Iron powder (13.5 g, 241 mmol) and 0.14 mL of conc. HCl 
were added to a mixture of sulfane 129 (6.63 g, 24 mmol) in 
ethanol/H2O (40 mL/10 mL). Then, the reaction mixture was refluxed until the 
starting material was completely consumed. After the reaction mixture was cooled to 
room temperature, it was passed through a pad of Celite 545, and washed with ethanol. 
The combined organic layers were dried over MgSO4. The product was obtained as a 
yellow solid in 83% yield after column chromatography on silica gel using 
pentane/EtOAc = 2/1 to EtOAc as eluents. 1H NMR (400 MHz, DMSO-d6) δ = 
7.51–7.48 (m, 4H), 6.56–6.53 (m, 4H), 5.80 (s, 4H); 13C NMR (100 MHz, DMSO-d6) 
δ = 152.0, 130.7, 128.9, 112.7. The spectroscopic data matched those reported in the 
literature. 
 
N, N´-[4, 4´-Thiobis(4,1-phenylene)]diacetamide (131)157,159 
Acetic anhydride (1.77 g, 17.3 mmol) was added to a 
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solution of compound 130 (1.56 g, 7.2 mmol) in dry DCM (10 mL) under argon, and 
the reaction mixture was stirred at room temperature. When the starting material was 
completely consumed (monitored by TLC), 150 mL of DCM was added, and the 
resulting solution was washed with a saturated aq. Na2CO3 solution. The organic layer 
was dried over MgSO4, and the volatiles were removed under reduced pressure. The 
product was obtained as a pale white solid in 64% yield after column chromatography 
on silica gel using EtOAc/pentane = 2/1 to EtOAc as eluents. 1H NMR (300 MHz, 
DMSO-d6) δ = 10.53 (s, 2H), 8.01–7.98 (m, 4H), 7.90–7.85 (m, 4H), 2.09 (s, 6H); 13C 
NMR (75 MHz, DMSO-d6) δ = 169.5, 145.1, 129.5, 129.1, 119.4, 24.2. The 
spectroscopic data matched those reported in the literature. 
 
N-Cyano-4, 4´-acetamidodiphenyl sulfilimine (132) 
Compound 132 was prepared according to a literature 
procedure.54,56 PhI(OAc)2 (708 mg, 2.2 mmol) was added 
to a solution of N,N´-[4,4´-thiobis(4,1-phenylene)] 
diacetamide (131) (601 mg, 2 mmol) and NH2CN (126 mg, 3 mmol) in DMF (10 mL) 
at 0 oC, and the reaction mixture was stirred at 0 oC for 30 min, then warmed up to 
room temperature. When the starting material was fully consumed (monitored by 
TLC), water (50 mL) was added, and the resulting mixture was extracted with DCM 
(4 × 30 mL). The combined organic layers were washed with a saturated aq. NaHCO3 
solution, water (three times) and brine, and dried over MgSO4. The product was 
obtained as a pale white solid in 47% yield after column chromatography on silica gel 
using EtOAc to DCM/methanol = 10/1 as eluents. The melting point is 232.4–233.7 
oC. 1H NMR (400 MHz, DMSO-d6) δ = 10.39 (s, 2H), 7.84–7.81(m, 4H), 7.70–7.66 
(m, 4H), 2.08 (s, 6H); 13C NMR (100 MHz, DMSO-d6) δ = 169.2, 143.3, 128.6, 128.5, 
120.3, 119.8, 24.1; IR (KBr): υ = 3259, 2142, 1526, 828 cm–1; MS (EI), m/z (relative 
intensity) 300 (100), 258 (37), 216 (47), 184 (20), 124 (19); HRMS (ESI), m/z: 
[M+Na]+ Calcd. for C17H16N4O2SNa 363.0886, found 363.0880. 
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N-Cyano-4, 4´-acetamidodiphenyl sulfoximine (133) 
Compound 133 was prepared according to a literature 
procedure.54,56 K2CO3 (736 mg, 5.33 mmol) and 70% 
m-CPBA (656 mg, 2.66 mmol) were added to a stirred 
solution of N-cyano-4,4´-acetamidodiphenylsulfilimine (132) (603 mg, 1.77 mmol) in 
MeOH (20 mL) at 0 oC, and the reaction mixture was stirred at room temperature until 
the starting material was fully consumed. After MeOH was removed under reduced 
pressure, water (20 mL) was added. The resulting mixture was extracted with DCM (4 
× 20 mL), and the combined organic layers were dried over MgSO4. The product was 
obtained as a white solid in 78% yield after column chromatography on silica gel 
using EtOAc as eluent. The melting point is 232.4–233.7 oC. 1H NMR (600 MHz, 
DMSO-d6) δ = 10.51 (s, 2H), 7.99 (d, J = 8.8 Hz, 4H), 7.87 (d, J = 8.8 Hz, 4H), 2.09 
(s, 6H); 13C NMR (125 MHz, DMSO-d6) δ = 169.4, 145.1, 129.5, 129.1, 119.4, 112.2, 
24.2; IR (KBr): υ = 3102, 2199, 1529, 830 cm–1; MS (EI), m/z (relative intensity) 156 
(100), 139 (80), 111 (56), 75 (69); HRMS (ESI), m/z: [M+H]+ Calcd. for 
C17H17N4O3S 357.1016, found 357.1016. 
 
4, 4´-Diaminodiphenyl sulfoximine (126) 
Compound 126 was prepared according to a literature 
procedure.160 Conc. HCl (3 mL) was added to a solution of 
N-cyano-4,4´-acetamidodiphenylsulfoximine (133) (356 mg, 
1 mmol) in ethanol (10 mL). Then, the reaction mixture was heated to reflux for 4 h 
and neutralized by a saturated aq. Na2CO3 solution until the pH value was about 8 
after it was cooled to room temperature. The resulting mixture was extracted with 
EtOAc (4 × 15 mL), and the combined organic layers were dried over MgSO4. The 
product was obtained as a white solid in 85% yield after column chromatography on 
silica gel by using DCM/methanol = 20/1 as eluents. The melting point is 124.6–126.0 
oC. 1H NMR (600 MHz, DMSO-d6) δ = 7.50 (d, J = 8.7 Hz, 4H), 6.55 (d, J = 8.7 Hz, 
4H); 13C NMR (125 MHz, DMSO-d6) δ = 152.0, 130.7, 128.9, 112.7; IR (KBr): υ = 
3343, 3213, 1588, 1087, 975, 826 cm–1; MS (EI), m/z (relative intensity) 247 [M]+ (7), 
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107 (100), 92 (8), 65 (13); HRMS (ESI), m/z: [M+H]+ Calcd. for C12H14N3OS 
248.0852, found 248.0844. 
 
2, 2´-[4, 4´-Thiobis(4,1-phenylene)]diisoindoline-1,3-dione (135) 
Compound 135 was prepared according to a 
literature procedure.161 Phthalic anhydride (326 
mg, 2.2 mmol) was added to a solution of 
4-(4-aminophenylthio)benzenamine (130) (433 mg, 2 mmol) in AcOH (10 mL). The 
reaction mixture was heated to reflux overnight. Then, AcOH was removed under 
reduced pressure after the reaction mixture was cooled to room temperature. The 
residue was diluted in 10 mL of water and filtrated. The residue was recrystallized 
from ethanol to give 2,2´-[4,4´-thiobis(4,1-phenylene)]diisoindoline-1,3-dione (135) 
as a white solid in 79% yield. The melting point is 207.1–209.2 °C. 1H NMR (600 
MHz, DMSO-d6) δ = 7.97–7.91 (m, 8H), 7.55–7.51 (m, 8H); 13C NMR (125 MHz, 
DMSO-d6) δ = 166.8, 134.8, 134.3, 131.5, 131.3, 131.1, 128.3, 123.5; IR (KBr): υ = 
1702, 1376, 1081, 814, 707 cm–1; MS (EI), m/z (relative intensity) 149 (11), 122 (56), 
105 (63), 83 (100); HRMS (ESI), m/z: [M+H]+ Calcd. for C28H17N2O4S 477.0904, 
found 477.0903. 
 
N-Cyano-4, 4´-diaminodiphenylsulfilimine (125) 
Compound 125 was prepared according to a literature 
procedure.162 PhI(OAc)2 was added (354 mg, 1.1 mmol) to a 
solution of 2,2´-[4,4´-thiobis(4,1-phenylene)]diisoindoline- 
1,3-dione (135) (477 mg, 1 mmol) and NH2CN (63 mg, 1.5 mmol) in DMF (10 mL) at 
0 oC, and the reaction mixture was stirred for 30 min at 0 oC, then warmed up to room 
temperature. When the starting material was fully consumed (monitored by TLC), the 
mixture was diluted in 30 mL of water, and the resulting mixture was extracted with 
DCM (4 × 20 mL). The combined organic layers were washed with a saturated aq. 
NaHCO3 solution, water and brine, and dried over MgSO4. After combined organic 
layers were concentrated under reduced pressure, the residue was dissolved in ethanol 
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(10 mL). Then, 60% aq. NH2NH2 (5 mL) was added and stirred at room temperature 
overnight. Water (50 mL) was added, and the resulting mixture was extracted with 
EtOAc (4 × 15 mL). The combined organic layers were dried over MgSO4. The 
product was obtained as a white solid in 32% overall yield after column 
chromatography on silica gel using DCM/methanol = 30/1 as eluents. The melting 
point is 162.1–163.4 oC. 1H NMR (600 MHz, DMSO-d6) δ = 7.32–7.30 (m, 4H), 
6.69–6.67 (m, 4H); 13C NMR (125 MHz, DMSO-d6) δ = 152.9, 129.1, 121.3, 119.6, 
113.9; IR (KBr): υ = 3328, 3211, 2125, 1586, 816, 744 cm–1; MS (EI), m/z (relative 
intensity) 216 (100), 184 (38), 124 (11), 80 (12); HRMS (ESI), m/z: [M+Na]+ Calcd. 
for C13H12N4SNa 279.0675, found 279.0676. 
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5.2.3 Procedures and product data for sulfonimidoyl 
fluorides 
N-Methyl benzenemethanesulfinamide (140a) 
Compound 140a was prepared according to a literature procedure.170 
SO2Cl2 (8.50 g, 63 mmol) was added to a solution of BnSH (3.73 g, 
30 mmol) in AcOH (1.80 g, 30 mmol) at -15 oC, and the reaction mixture was stirred 
for 30 min at -15 oC, then warmed to room temperature and stirred for another 2 h. 
The volatiles were removed under vacuum. The crude sulfinic chloride was dissolved 
in 10 mL of diethyl ether and used for the next step without further purification. 
The resulting solution of crude sulfinic chloride was added dropwise to a mixture of 
40% aq. CH3NH2 solution (20 mL) and diethyl ether (20 mL). After the addition, the 
mixture was stirred for 1 h at room temperature. Then, water (50 mL) was added, and 
the resulting mixture was extracted with CH2Cl2 (4 × 20 mL). The combined organic 
layers were dried over MgSO4. The product was obtained as a pale yellow solid in 
78% yield after column chromatography on silica gel using DCM/methanol = 50/1 as 
eluents. The melting point is 69.7–71.6 oC. 1H NMR (600 MHz, CDCl3) δ = 
7.38–7.33 (m, 3H), 7.29–7.28 (m, 2H), 4.01 (d, J = 13.0 Hz, 1H), 3.89 (d, J = 13.0 Hz, 
1H), 3.58–3.51 (m, 1H), 2.76–2.74 (m, 3H); 13C NMR (150 MHz, CDCl3) δ = 130.4, 
129.3, 128.8, 128.2, 59.9, 28.1. IR (ATR): υ = 3131, 2901, 1488, 1449, 1036, 876, 771, 
682 cm-1; MS (EI), m/z (relative intensity) 169 [M]+ (5), 91 (100), 65 (11), 51 (1); 
HRMS (ESI), m/z: [M+H]+ Calcd. for C8H12NOS 170.0634, found 170.0633. 
 
N-Benzyl benzenemethanesulfinamide (140b) 
Compound 140b was prepared according to a literature 
procedure.170 SO2Cl2 (4.25 g, 31.5 mmol) was added to a 
solution of BnSH (1.86 g, 15 mmol) in AcOH (0.90 g, 15 mmol) 
at -15 oC, and the reaction mixture was stirred for 30 min at the same temperature, 
then warmed to room temperature and stirred for another 2 h. The volatiles were 
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removed under vacuum. The crude sulfinic chloride was dissolved in 10 mL of diethyl 
ether and used in the next step without further purification. 
The solution of crude sulfinic chloride was added dropwise to a solution of BnNH2 
(0.32 g, 3 mmol) in 20 mL of diethyl ether. After the addition, the mixture was stirred 
for 1 h at room temperature. Then, water (50 mL) was added, and the resulting 
mixture was extracted with DCM (4 × 20 mL). The combined organic layers were 
dried over MgSO4. The product was obtained as a pale yellow solid in 42% yield after 
column chromatography on silica gel using DCM/methanol = 50/1 as eluents. The 
melting point is 72.3–73.7 oC. 1H NMR (600 MHz, CDCl3) δ = 7.42–7.20 (m, 10H), 
4.27–4.24 (m, 2H), 4.07 (d, J = 13.0 Hz, 1H), 3.97 (d, J = 13.0 Hz, 1H), 3.90 (t, J = 
6.1 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ = 138.0, 130.5, 129.3, 128.8, 128.6, 
128.3, 128.0, 127.7, 60.9, 46.9; IR (ATR): υ = 3188, 3027, 2901, 1740, 1492, 1452, 
1420, 1043, 804, 737, 692 cm-1; MS (EI), m/z (relative intensity) 384 (11), 336 (100), 
246 [M+H]+ (28), 24 [M]+ (25), 91 (44), 85 (53); Anal. Calcd. for C14H15NOS: C 
68.54, H 6.16, N 5.71, Found: C 68.45, H 6.19, N 5.63. 
 
N-Methyl and N-benzyl phenylmethanesulfonimidoyl fluoride (137a and 137b) 
Compounds 137a, 137b were prepared according to a literature procedure.62,64 
t-BuOCl (0.16 g, 1.5 mmol) was added to a solution of sulfinimide 140a (0.17 g, 1 
mmol) or sulfinimide 140b (0.25 g, 1 mmol) in 5 mL of DCM at 0 oC. Then, the 
mixture was stirred for 30 min at 0 oC. Subsequently, the volatiles were removed 
under vacuum. The crude sulfonimidoyl chlorides (141a or 141b) were dissolved in 5 
mL of CH3CN under argon and used directly for the next step.  
AgF (1.2 equiv.) was added to the solution of sulfonimidoyl chlorides (141a or 141b) 
in CH3CN under argon, and the resulting reaction mixture was stirred for 24 h at room 
temperature. The precipitate was removed by filtration and washed with DCM. The 
filtrate was concentrated under reduced pressure. 
 
Product 137a was obtained as a white solid in 45% yield after column 
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chromatography on silica gel by using pentane/EtOAc = 10/1 as eluents. The melting 
point is 50.9–52.1 oC. 1H NMR (600 MHz, CDCl3) δ = 7.50–7.35 (m, 5H), 4.58 (d, J 
= 14.1 Hz, 1H), 4.52 (d, J = 14.1 Hz, 1H), 2.89 (d, J = 10.1 Hz, 3H); 19F NMR (564 
MHz, CDCl3) δ = 72.49 (q, J = 9.9); 13C NMR (150 MHz, CDCl3) δ = 130.9, 129.4, 
128.9, 127.2, 58.5 (d, J = 22.9 Hz), 29.2 (d, J = 4.0 Hz). IR (ATR): υ = 3071, 2992, 
2934, 2838, 1739, 1497, 1435, 1312, 1187, 732, 698 cm-1; MS (EI), m/z (relative 
intensity) 173 (1), 158 (1), 125 (100), 91 (7), 78 (2); MS (ESI), m/z 210.04 [M+Na]+; 
HRMS (ESI), m/z: [M+Na]+ Calcd. for C8H10NOSFNa 210.0359, found 210.0363. 
 
Product 137b was obtained as a white solid in 49% yield after column 
chromatography on silica gel using pentane/EtOAc = 15/1 as eluents. 
The melting point is 47.3–49.1 oC. 1H NMR (600 MHz, CDCl3) δ = 7.50–7.46 (m, 
2H), 7.44 (t, J = 7.6 Hz, 3H), 7.31 (t, J = 7.4 Hz, 2H), 7.26 (t, J = 7.6 Hz, 3H), 4.67 (d, 
J = 14.1 Hz, 1H), 4.59 (d, J = 14.1 Hz, 1H), 4.45 (qd, J = 14.5, 9.0 Hz, 2H); 19F NMR 
(564 MHz, CDCl3) δ = 76.34 (t, J = 8.9 Hz); 13C NMR (151 MHz, CDCl3) δ = 139.24 
(d, J = 5.7 Hz), 131.0, 129.5, 128.9, 128.4, 127.2, 127.0, 1267.0, 58.9 (d, J = 23.1 Hz), 
46.5 (d, J = 4.1 Hz); MS (EI), m/z (relative intensity) 243 (1), 196 (13), 171 (10), 105 
(2), 91 (100), 77 (7); MS (CI), m/z 264 [M+H]+; HRMS (ESI), m/z: [M+Na]+ Calcd. 
for C14H14ONFSNa 286.0672, found 286.0672. 
 
Benzenemethanesulfinamide (143) 
Compound 143 was prepared according to a literature procedure.170 
SO2Cl2 (8.50 g, 63 mmol) was added to a solution of BnSH (3.73 g, 30 
mmol) in AcOH (1.80 g, 30 mmol) at -15 oC, and the reaction mixture was stirred for 
30 min at -15 oC, then warmed to room temperaure and stirred for another 2 h. After 
the volatiles were removed under vacuum, the crude sulfinic chloride was dissolved in 
10 mL of diethyl ether and used directly in the next step without further purification. 
The solution of crude sulfinic chloride was added dropwise to a mixture of a saturated 
aq. NH3 solution (20 mL) and diethyl ether (20 mL). After the addition, the mixture 
was stirred for 1 h at room temperaure. Then, water (50 mL) was added, and the 
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resulting mixture was extracted with DCM (3 × 20 mL). The combined organic layers 
were dried over MgSO4 and the volatiles were removed under reduced pressure. 
Benzenemethanesulfinamide (143) was obtained as a white solid in 48% yield after 
column chromatography on silica gel using DCM/methanol = 30/1 as eluents. The 
melting point is 125.4–127.3 oC. 1H NMR (400 MHz, CD3OD) δ = 7.39–7.23 (m, 5H), 
4.05 (d, J = 12.8 Hz, 1H), 3.96 (d, J = 12.8 Hz, 1H); 13C NMR (100 MHz, CD3OD) δ 
= 130.6, 130.2, 128.3, 127.7, 61.9; IR (ATR): υ = 3241, 3081, 1747, 1577, 1493, 1454, 
1179, 993, 773, 697 cm–1; MS (EI), m/z (relative intensity) 91 (30), 85 (100), 78 (36), 
68 (13); HRMS (ESI), m/z: [M+Na]+ Calcd. for C7H9ONNaS 178.0297, found 
178.0296. 
 
N-Boc benzenemethanesulfinamide (144) 
NaH (86.4 mg, 3.6 mmol, 60% in oil) was added to a solution of 
benzenemethanesulfinamide (143) (465.6 mg, 3 mmol) in DCM (20 
mL) at 0 oC, and the reaction mixture was stirred for 30 min. Then, a solution of 
Boc2O (1.31 g, 6 mmol) in DCM (5 mL) was added dropwise to the stirring mixture at 
0 oC and stirred for another 16 h at room temperature. Subsequently, water (50 mL) 
was added, and the resulting mixture was extracted with DCM (3 × 20 mL). The 
combined organic layers were dried over MgSO4. The desired product was obtained 
as white solid in 38% yield after column chromatography on silica gel using 
DCM/methanol = 50/1 as eluents. The melting point is 127.9–130.0 oC. 1H NMR (400 
MHz, CD3OD) δ = 7.43–7.17 (m, 5H), 4.25 (d, J = 12.8 Hz, 1H), 4.18 (d, J = 12.8 Hz, 
1H), 1.42 (s, 9H); 13C NMR (100 MHz, CD3OD) δ = 153.5, 130.0, 129.9, 128.5, 
128.1, 82.2, 59.5, 26.9; IR (ATR): υ = 3109, 2981, 1723, 1433, 1368, 1241, 1152, 
1052, 820, 7575, 708 cm-1; MS (EI), m/z (relative intensity) 511 [2M+H]+ (100), 254 
[M]+ (7), 198 (10), 91 (38), 86 (53); Anal. Calcd. for C12H17NO3S: C 56.45, H 6.71, N 
5.49, Found: C 56.48, H 6.39, N 5.48. 
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1-(Benzyloxy)-4-bromobenzene (159)192 
A mixture of 4-bromophenol (8.65 g, 50 mmol), K2CO3 (13.80 g, 
100 mmol), (bromomethyl)benzene (10.26 g, 60 mmol) and 
acetone (100 mL) was stirred for 16 h at room temperaure. Then, 
the precipitate was removed by filtration and washed with acetone. The filtrate was 
concentrated under reduced pressure. The product was obtained as a white solid in 
80% yield after column chromatography on silica gel using pentane/EtOAc = 50/1 as 
eluents. 1H NMR (400 MHz, CDCl3) δ = 7.50–7.27 (m, 7H), 6.85 (dd, J = 8.7, 1.6 Hz, 
2H), 5.03 (s, 2H); 13C NMR (100 MHz, CDCl3) δ = 157.8, 136.5, 132.3, 128.6, 128.1, 
127.4, 116.7, 113.1, 70.2. The spectroscopic data matched those reported in the 
literature. 
 
1-(Benzyloxy)-4-(5-bromopentyl)benzene (160)180 
n-BuLi (6 mmol, 1.6 M in hexane) was added to a solution 
of 1-(benzyloxy)-4-bromobenzene (159) (1.32 g, 5 mmol) in 
dry THF (10 mL) at -78 oC, and the reaction mixture was stirred at -78 oC for 30 min. 
Subsequently, a solution of dibromopentane (1.38 g, 6 mmol) in dry THF (2 mL) was 
added dropwise to the reaction mixture and stirred for another 10 min at -78 oC after 
the addition. Then, the reaction mixture was warmed to room temperature and stirred 
for another 2 h. Water (20 mL) was added, and the resulting minxture was extracted 
with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO4, and 
the volatiles were removed under reduced pressure. The product was obtained as a 
yellow solid in 43% yield after column chromatography on silica gel using 
pentane/EtOAc = 35/1 as eluents. 1H NMR (400 MHz, CDCl3) δ = 7.38 (ddd, J = 24.9, 
15.7, 7.2 Hz, 5H), 7.10 (d, J = 8.2 Hz, 2H), 6.91 (d, J = 8.1 Hz, 2H), 5.05 (s, 2H), 
3.40 (t, J = 6.8 Hz, 2H), 2.57 (t, J = 7.6 Hz, 2H), 1.99–1.81 (m, 2H), 1.69–1.55 (m, 
2H), 1.54–1.37 (m, 2H); 13C NMR (100 MHz, CDCl3) δ = 157.0, 137.2, 134.7, 129.3, 
128.5, 127.9, 127.5, 114.7, 70.0, 34.8, 33.8, 32.7, 30.8, 27.8. The spectroscopic data 
matched those reported in the literature. 
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S-{5-[4-(Benzyloxy)phenyl]pentyl}thioacetate (161) 
AcSH (738 mg, 9.7 mmol) was added to the mixture of 
1-(benzyloxy)-4-(5-bromopentyl)benzene (160) (2.70 g, 
8.1 mmol), K2CO3 (1.68 g, 12.2 mmol), KI (133 mg, 
0.8 mmol) and acetone (50 mL) at room temperaure, and the reaction mixture was 
stirred for 16 h. Then, the precipitate was removed by filtration and washed with 
acetone. The filtrate was concentrated under reduced pressure. The product was 
obtained as a yellow solid in 43% yield after column chromatography on silica gel 
using pentane/EtOAc = 50/1 as eluents. The melting point is 37.5–38.6 oC. 1H NMR 
(600 MHz, CDCl3) δ = 7.44 (d, J = 7.6 Hz, 2H), 7.39 (t, J = 7.2 Hz, 2H), 7.32 (t, J = 
7.0 Hz, 1H), 7.09 (d, J = 7.0 Hz, 2H), 6.90 (dd, J = 8.4, 1.6 Hz, 2H), 5.05 (s, 2H), 
2.92–2.84 (m, 2H), 2.55 (t, J = 7.6 Hz, 2H), 2.32 (d, J = 0.8 Hz, 3H), 1.65–1.54 (m, 
4H), 1.45–1.34 (m, 2H); 13C NMR (150 MHz, CDCl3) δ = 195.9, 156.9, 137.2, 134.8, 
129.3, 128.5, 127.9, 127.5, 114.7, 70.0, 34.8, 31.1, 30.6, 29.4, 29.0, 28.4. IR (ATR): υ 
= 3014, 2921, 2854, 1693, 1610, 1508, 1459, 1242, 1122, 1010, 957, 821, 737 cm-1; 
MS (EI), m/z (relative intensity) 328 [M]+ (24), 195 (8), 162 (4), 107 (5), 91 (100), 65 
(8); MS (ESI), m/z 351.14 [M+Na]+, 329.16 [M+H]+; HRMS (ESI), m/z: [M+Na]+ 
Calcd. for C20H24O2NaS 351.1389, found 351.1384. 
 
N-Methyl-S-{5-[4-(benzyloxy)phenyl]pentyl}sulfinamide (162) 
Compound 162 was prepared according to a literature 
procedure.170 SO2Cl2 (1.04 g, 7.7 mmol) was added to 
a solution of S-{5-[4-(benzyloxy)phenyl]pentyl}thioacetate (161) (1.18 g, 3.6 mmol) 
and Ac2O (368 mg, 3.6 mmol) in DCM (5 mL) at -15 oC, and the reation mixture was 
stirred for 30 min at -15 oC, then warmed up to room temperature and stirred for 
another 2 h. The volatiles were removed under vacuum. The crude sulfinic chloride 
was dissolved in 10 mL of diethyl ether and used in the next step directly without 
further purification. 
The solution of crude sulfinic chloride was added dropwise to a mixture of 40% aq. 
CH3NH2 solution (5 mL) and diethyl ether (20 mL). After the addition, the reaction 
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mixture was stirred for 1 h at room temperature. Then, water (50 mL) was added, and 
the resulting mixture was extracted with DCM (4 × 20 mL). The combined organic 
layers were dried over MgSO4 and the volatiles were removed under reduced pressure. 
The product was obtained as a pale yellow solid in 78% yield after column 
chromatography on silica gel using DCM/methanol = 30/1 as eluents. The melting 
point is 68.1–69.9 oC. 1H NMR (600 MHz, CDCl3) δ = 7.43 (d, J = 7.5 Hz, 2H), 7.37 
(t, J = 7.5 Hz, 2H), 7.31 (t, J = 7.3 Hz, 1H), 7.07 (d, J = 8.5 Hz, 2H), 6.89 (d, J = 8.5 
Hz, 2H), 5.03 (s, 2H), 2.79–2.64 (m, 5H), 2.56 (t, J = 7.6 Hz, 2H), 1.71–1.58 (m, 4H), 
1.50–1.39 (m, 2H); 13C NMR (150 MHz, CDCl3) δ = 157.0, 137.2, 134.6, 129.2, 
128.5, 127.9, 127.5, 114.7, 70.0, 54.2, 34.7, 31.2, 28.2, 27.3, 23.1; IR (ATR): υ = 3159, 
2926, 2864, 1602, 1504, 1460, 1234, 1025, 827, 741, 688 cm-1; MS (EI), m/z (relative 
intensity) 331 [M]+ (1), 301 (3), 300 (15), 238 (11), 197 (4), 91 (100), 65 (5); MS 
(ESI), m/z 354.15 [M+Na]+, 332.17 [M+H]+. HRMS (ESI), m/z: [M+Na]+ Calcd. for 
C19H25O2NNaS 354.1498, found 354.1491. 
 
N-Methyl-S-{5-[4-(benzyloxy)phenyl]pentyl}sulfonimidoyl fluoride (151a) 
Compound 151a was prepared according to a literature 
procedure.62,64 t-BuOCl (163 mg, 1.5 mmol) was added to 
the solution of sulfinamide 162 (331 mg, 1 mmol) in 5 
mL of DCM at 0 oC, and the reaction mixture was stirred for 30 min at 0 oC. 
Subsequently, the volatiles were removed under vacuum. The crude sulfonimidoyl 
chloride was used in the next step directly. 
AgF (1.2 equiv.) was added to a solution of crude sulfonimidoyl chloride in CH3CN 
(5 mL) under argon, and the reaction mixture was stirred for 24 h at room temperature. 
The precipitate was removed by filtration and washed with DCM. The filtrate was 
concentrated under reduced pressure. The product was obtained as a colorless oil in 
50% yield after column chromatography using pentane/EtOAc = 10/1 as eluents. 1H 
NMR (600 MHz, CDCl3) δ = 7.44 (d, J = 7.5 Hz, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.33 (t, 
J = 7.3 Hz, 1H), 7.08 (d, J = 8.6 Hz, 2H), 6.91 (d, J = 8.6 Hz, 2H), 5.05 (s, 2H), 
3.38–3.23 (m, 2H), 2.92 (d, J = 9.7 Hz, 3H), 2.57 (t, J = 7.6 Hz, 2H), 1.95 (dt, J = 
BnO
S
O
N
F
Me
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15.7, 7.9 Hz, 2H), 1.64 (dt, J = 15.3, 7.6 Hz, 2H), 1.46 (dt, J = 15.4, 7.7 Hz, 2H); 19F 
NMR (564 MHz, CDCl3) δ = 72.02 (q, J = 9.7 Hz); 13C NMR (151 MHz, CDCl3) δ = 
157.0 137.2, 134.2, 129.3, 128.6, 127.9, 127.5, 114.7, 70.0, 52.8 (d, J = 20.1 Hz), 34.5, 
30.9, 28.7 (d, J = 3.7 Hz), 27.4, 23.8. IR (ATR): υ = 3033, 2932, 2859, 2323, 2091, 
1607, 1508, 1451, 1323, 1204, 1115, 1018, 826, 736, 695 cm-1; MS (EI), m/z (relative 
intensity) 130 (2), 117 (6), 107 (4), 91 (100), 78 (9); MS (ESI), m/z 350.16 [M+H]+, 
372.14 [M+Na]+; HRMS (ESI), m/z: [M+Na]+ Calcd. for C19H24O2NFNaS 372.1404, 
found 372.1401. 
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5.2.4 Procedures and product data for the N-alkynylation of 
N-H sulfoximines with bromoacetylenes 
5.2.4.1 General procedures for the preparation of 
bromoacetylenes  
5.2.4.1.1 General procedure A (GPA)193,194 
 
 
N-Bromosuccinimide (2.14 g, 12 mmol) and AgNO3 (170 mg, 1 mmol) were added to 
a solution of the corresponding alkyne (10 mmol) in acetone (50 mL), and the 
reaction mixture was stirred for 5 h at room temperature. Then, the reaction mixture 
was filtered under reduced pressure, and the filtrate was poured into water (50 mL). 
The liquid mixture was extracted with Et2O (3 × 30 mL). The combined organic 
layers were washed with brine and dried over MgSO4. The filtrate was concentrated 
under reduced pressure after filtration. The product was obtained after column 
chromatography on silica gel. 
5.2.4.1.2 General procedure B (GPB1 and GPB2)192 
 
GPB1: Triphenyl phosphine (10.5 g, 40 mmol) was added to the mixture of aldehyde 
(10 mmol) and carbon tetrabromide (6.63 g, 20 mmol) in DCM (25 mL) at 0 °C under 
argon portionwise over 15 min. Then, the mixture was stirred for 5 h at 0 °C under 
argon and quenched with Et2O (100 mL). The mixture was filtered through a pad of 
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silica gel under reduced pressure and washed with Et2O. The filtrate was concentrated, 
and the product was obtained after column chromatography on silica gel.  
 
GPB2: BnEt3Cl and a solution of KOH (12.9 g, 230 mmol) in water (10 mL) were 
added to the vigorously stirred solution of 1,1-dibromoethene (5 mmol) from GPB1 in 
DCM (25 mL) at 0 °C. Reaction mixture was stirred for 5 h at 0 °C and quenched by 
the addition of 20 mL of water. The organic layer was separated, and the aqueous 
layer was extracted with DCM (3 × 20 mL). The combined organic layers were 
washed with brine and dried over MgSO4. The filtrate was concentrated under 
reduced pressure after filtration. The product was obtained after column 
chromatography on silica gel.  
5.2.4.2 General procedure for the preparation of N-alkynylated 
sulfoximines (GPC) 
Sulfoximine (0.6 mmol), Cu(OAc)2 (9.1 mg, 0.05 mmol), 1,10-phenanthroline 
(18.0 mg, 0.1 mmol) and K2CO3 (172.5 mg, 1.25 mmol) were added into a 10 mL 
Schlenk tube. The Schlenk tube was evacuated, and then refilled with argon (3 times 
repeated). Subsequently, the corresponding bromoacetylene (0.5 mmol) and toluene 
were added under argon. The Schlenk tube was heated to 60 °C for 48 h after tightly 
sealed with a stopper. The reaction mixture was passed through a pad of Celite 545 
and  washed with acetone/Et3N (50/1) before purification. The N-alkynylated 
sulfoximines were purified after column chromatography on basic Al2O3 or 
deactivated basic Al2O3.  
Deactivation procedure: A beaker was filled with normal basic Al2O3 to a 
volume level of 200 mL. Then 10 mL of water was added. 
 
N-Phenylethynyl-S-methyl-S-phenylsulfoximine (90a)101 
According to GPC, product 90a was prepared from 
S
Me
O N
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S-methyl-S-phenylsulfoximine and (bromoethynyl)benzene  and obtained as a 
yellow oil in 72% yield after column chromatography on basic Al2O3 using 
pentane/EtOAc/Et3N = 25/25/1 as eluents. 1H NMR (400 MHz, CDCl3)  = 8.02 (d, J 
= 7.5 Hz, 2H), 7.69 (t, J = 7.4 Hz, 1H), 7.61 (t, J = 7.6 Hz, 2H), 7.24–7.21 (m, 2H), 
7.18–7.06 (m, 3H), 3.27 (s, 3H); 13C NMR (100 MHz, CDCl3)  = 137.4, 134.4, 131.3, 
129.8, 128.4, 128.0, 126.0, 125.6, 87.8, 59.1, 43.7. The spectroscopic data matched 
those reported in the literature. 
 
N-(4-Methyl-phenylethynyl)-S-methyl-S-phenylsulfoximine (90b)101 
According to GPC, product 90b was prepared from 
S-methyl-S-phenylsulfoximine and 1-(bromoethynyl)-4- 
methylbenzene and obtained as a yellow solid in 71% 
yield after column chromatography on basic Al2O3 using pentane/EtOAc/Et3N = 
25/25/1 as eluents. The melting point is 136.1–137.2 °C. 1H NMR (600 MHz, CDCl3) 
 = 8.03 (d, J = 7.5 Hz, 2H), 7.70 (t, J = 7.4 Hz, 1H), 7.62 (t, J = 7.8 Hz, 2H), 7.13 (d, 
J = 8.1 Hz, 2H), 6.98 (d, J = 8.0 Hz, 2H), 3.28 (s, 3H), 2.27 (s, 3H); 13C NMR (150 
MHz, CDCl3)  = 137.3, 135.8, 134.3, 131.1, 129.7, 128.7, 128.4, 122.3, 86.7, 58.9, 
43.6, 21.3. The spectroscopic data matched those reported in the literature. 
 
N-(4-Methoxy-phenylethynyl)-S-methyl-S-phenylsulfoximine (90c)101 
According to the GPC, product 90c was prepared from 
S-methyl-S-phenylsulfoximine and 1-(bromoethynyl)-4- 
methoxybenzene and obtained as a pale yellow solid in 
34% yield after column chromatography on deactivated basic Al2O3 using 
pentane/EtOAc/Et3N = 25/25/1 as eluents. The melting point is 102.9–104.5 °C. 1H 
NMR (600 MHz, CDCl3)  = 8.04 (d, J = 8.0 Hz, 2H), 7.71 (t, J = 7.4 Hz, 1H), 7.63 (t, 
J = 7.8 Hz, 2H), 7.18 (d, J = 8.8 Hz, 2H), 6.73 (d, J = 8.8 Hz, 2H), 3.75 (s, 3H), 3.28 
(s, 3H); 13C NMR (150 MHz, CDCl3)  = 158.1, 137.6, 134.4, 132.7, 129.8, 128.5, 
117.7, 113.7, 85.8, 58.6, 55.4, 43.8. The spectroscopic data matched those reported in 
the literature. 
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N-(4-Chloro-phenylethynyl)-S-methyl-S-phenylsulfoximine (90d) 
According to GPC, product 90d was prepared from 
S-methyl-S-phenylsulfoximine and 1-(bromoethynyl)-4- 
chlorobenzene and obtained as a yellow solid in 86% yield 
after column chromatography on basic Al2O3 using pentane/EtOAc/Et3N = 25/25/1 as 
eluents. The melting point is 146.7–147.8 °C. 1H NMR (600 MHz, CDCl3)  = 8.02 (d, 
J = 7.5 Hz, 2H), 7.71 (t, J = 7.4 Hz, 1H), 7.63 (t, J = 7.8 Hz, 2H), 7.13 (s, 4H), 3.28 (s, 
3H); 13C NMR (150 MHz, CDCl3)  = 137.4, 134.5, 132.5, 131.7, 129.9, 128.4, 128.3, 
124.2, 88.7, 58.1, 43.9; IR (ATR): υ = 3016, 2189, 1487, 1337, 1213, 1089, 980, 816, 
741, 683 cm-1; MS (EI), m/z (relative intensity) 289 [M]+ (7), 149 (7), 140 (4), 124 
(100), 114 (23), 109 (5), 77 (11), 51 (12); MS (ESI), m/z 290.04 [M+H]+; HRMS 
(ESI), m/z: [M+Na]+ Calcd. for C15H12NOSClNa 312.0220, found 312.0219. 
 
N-(4-Bromo-phenylethynyl)-S-methyl-S-phenylsulfoximine (90e) 
According to GPC, product 90e was prepared from 
S-methyl-S-phenylsulfoximine and 1-(bromoethynyl)-4-
bromobenzene and obtained as a yellow solid in 82% yield 
after column chromatography on basic Al2O3 using pentane/EtOAc/Et3N = 25/25/1 as 
eluents. The melting point is 146.7–147.8 °C. 1H NMR (600 MHz, CDCl3)  = 8.01 (d, 
J = 7.5 Hz, 2H), 7.71 (t, J = 7.4 Hz, 1H), 7.63 (t, J = 7.8 Hz, 2H), 7.27 (d, J = 8.5 Hz, 
2H), 7.07 (d, J = 8.5 Hz, 2H), 3.28 (s, 3H); 13C NMR (150 MHz, CDCl3)  = 137.2, 
134.5, 132.8, 131.2, 129.9, 128.4, 124.7, 119.7, 89.0, 58.2, 43.9; IR (ATR): υ = 3014, 
2187, 1482, 1335, 1213, 1087, 980, 874, 811, 739, 682 cm-1; MS (EI), m/z (relative 
intensity) 140 (13), 124 (100), 114 (48), 109 (8), 97 (17), 91 (10), 77 (24), 51 (20); 
MS (ESI), m/z 333.99 [M+H]+; HRMS (ESI), m/z: [M+Na]+ Calcd. for 
C15H12NOSBrNa 355.9715, found 355.9717. 
 
N-(4-Nitro-phenylethynyl)-S-methyl-S-phenylsulfoximine 90f101 
According to GPC, product 90f was prepared from 
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S-methyl-S-phenylsulfoximine and 1-(bromoethynyl)4-nitrobenzene and obtained as a 
dark yellow solid in 43% yield after column chromatography on deactivated basic 
Al2O3 using pentane/EtOAc/Et3N = 25/25/1 as eluents. The melting point is 
117.4–118.9 °C. 1H NMR (600 MHz, CDCl3)  = 8.04–8.03 (m, 4H), 7.77 (t, J = 7.5 
Hz, 1H), 7.68 (t, J = 7.8 Hz, 2H), 7.29 (d, J = 8.9 Hz, 2H), 3.33 (s, 3H); 13C NMR 
(150 MHz, CDCl3)  = 145.3, 137.0, 134.8, 133.6, 131.5, 130.0, 128.4, 123.5, 95.0, 
59.1, 44.2. The spectroscopic data matched those reported in the literature. 
 
N-(2-Methyl-phenylethynyl)-S-methyl-S-phenylsulfoximine (90g)101 
According to GPC, product 90g was prepared from 
S-methyl-S-phenylsulfoximine and 1-(bromoethynyl)-2-
methylbenzene and obtained as a yellow oil in 74% yield after 
column chromatography on basic Al2O3 using pentane/EtOAc/Et3N = 25/25/1 as 
eluents. 1H NMR (600 MHz, CDCl3)  = 8.03 (d, J = 7.4 Hz, 2H), 7.70 (t, J = 7.4 Hz, 
1H), 7.62 (t, J = 7.7 Hz, 2H), 7.20 (dd, J = 7.2, 1.5 Hz, 1H), 7.06 (d, J = 7.0 Hz, 1H), 
7.04–6.98 (m, 2H), 3.29 (s, 3H), 2.16 (s, 3H); 13C NMR (150 MHz, CDCl3)  = 139.3, 
137.3, 134.3, 131.3, 129.8, 129.0, 128.5, 126.0, 125.3, 92.0, 57.9, 43.7, 20.8. The 
spectroscopic data matched those reported in the literature. 
 
N-(2-Chloro-phenylethynyl)-S-methyl-S-phenylsulfoximine (90i) 
According to GPC, product 90i was prepared from 
S-methyl-S-phenylsulfoximine and 1-(bromoethynyl)-2-
chlorobenzene and obtained as a yellow oil in 81% yield after 
column chromatography on basic Al2O3 using pentane/EtOAc/Et3N = 25/25/1 as 
eluents. 1H NMR (600 MHz, CDCl3)  = 8.05 (d, J = 7.6 Hz, 2H), 7.70 (t, J = 7.4 Hz, 
1H), 7.62 (t, J = 7.8 Hz, 2H), 7.26 (td, J = 7.6, 1.5 Hz, 2H), 7.07–7.01 (m, 2H), 3.35 
(s, 3H); 13C NMR (150 MHz, CDCl3)  = 137.2, 135.1, 134.5, 132.6, 129.8, 128.8, 
128.4, 126.8, 126.2, 125.4, 93.7, 56.5, 43.6; IR (ATR): υ = 3017, 2195, 1438, 1345, 
1217, 1113, 968, 874, 744, 681 cm-1; MS (EI), m/z (relative intensity) 289 [M]+ (8), 
182 (4), 149 (11), 140 (11), 124 (100), 114 (33), 109 (7), 97 (11), 91 (9), 77 (13), 51 
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(9); MS (ESI), m/z 290.04 [M+H]+; Anal. Calcd. for C15H12NOSCl: C 62.17, H 4.17, 
N 4.83, found: C 62.01, H 3.90, N 4.6. 
 
N-(2-Bromo-phenylethynyl)-S-methyl-S-phenylsulfoximine (90j) 
According to GPC, product 90j was prepared from 
S-methyl-S-phenylsulfoximine and 1-(bromoethynyl)-2-
bromobenzene and obtained as a yellow oil in 85% yield after 
column chromatography on basic Al2O3 using pentane/EtOAc/Et3N = 25/25/1 as 
eluents. 1H NMR (600 MHz, CDCl3)  = 8.04 (d, J = 7.5 Hz, 2H), 7.69 (t, J = 7.4 Hz, 
1H), 7.61 (t, J = 7.8 Hz, 2H), 7.43 (dd, J = 8.0, 0.6 Hz, 1H), 7.25 (dd, J = 7.8, 1.5 Hz, 
1H), 7.10 (td, J = 7.6, 0.9 Hz, 1H), 6.94 (td, J = 7.7, 1.5 Hz, 1H), 3.35 (s, 3H); 13C 
NMR (150 MHz, CDCl3)  = 137.2, 134.5, 132.6, 131.9, 129.8, 128.4, 127.6, 127.0, 
126.8, 125.2, 93.2, 58.4, 43.7; IR (ATR): υ = 3017, 2195, 1437, 1344, 1217, 1107, 967, 
873, 741, 684 cm-1; MS (EI), m/z (relative intensity) 333 [M]+ (1), 140 (9), 124 (100), 
114 (42), 109 (6), 91 (7), 77 (14), 51 (12); MS (ESI), m/z 335.99 [[M+H]+, 81Br]; 
HRMS (ESI), m/z: [M+H]+ Calcd. for C15H13NOSBr 333.9896, found 333.9903. 
 
N-(3-Methoxy-phenylethynyl)-S-methyl-S-phenylsulfoximine (90k) 
According to GPC, product 90k was prepared from 
S-methyl-S-phenylsulfoximine and 1-(bromoethynyl)-3-
methoxybenzene and obtained as a yellow oil in 62% yield 
after column chromatography on deactivated basic Al2O3 using pentane/EtOAc/Et3N 
= 25/25/1 as eluents. 1H NMR (600 MHz, CDCl3)  = 8.02 (d, J = 7.6 Hz, 2H), 7.70 (t, 
J = 7.4 Hz, 1H), 7.62 (t, J = 7.8 Hz, 2H), 7.07 (t, J = 8.0 Hz, 1H), 6.82 (d, J = 7.6 Hz, 
1H), 6.78 (d, J = 2.0 Hz, 1H), 6.69 (dd, J = 8.3, 2.5 Hz, 1H), 3.72 (s, 3H), 3.28 (s, 3H); 
13C NMR (150 MHz, CDCl3)  = 159.2, 137.3, 134.4, 129.8, 129.0, 128.4, 126.7, 
123.9, 116.2, 112.6, 87.7, 59.0, 55.2, 43.8; IR (ATR): υ = 3011, 2204, 1574, 1446, 
1339, 1213, 1102, 1037, 972, 918, 781, 742, 685 cm-1; MS (EI), m/z (relative intensity) 
285 [M]+ (26), 145 (4), 140 (23), 124 (100), 91 (11), 77 (19), 51 (15); MS (ESI), m/z 
286.09 [M+H]+; HRMS (ESI), m/z: [M+Na]+ Calcd. for C16H15NO2SNa 308.0716, 
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found 308.0718.  
 
N-(3-Chloro-phenylethynyl)-S-methyl-S-phenylsulfoximine (90l) 
According to GPC, product 90l was prepared from 
S-methyl-S-phenylsulfoximine and 1-(bromoethynyl)-3-
chlorobenzene and obtained as a yellow oil in 71% yield after 
column chromatography on basic Al2O3 using pentane/EtOAc/Et3N = 25/25/1 as 
eluents. 1H NMR (600 MHz, CDCl3)  = 8.03–8.01 (m, 2H), 7.73–7.71 (m, 1H), 
7.65–7.63 (m, 2H), 7.182–7.18 (m, 1H), 7.08 (m, 3H), 3.29 (s, 3H); 13C NMR (150 
MHz, CDCl3)  = 137.2, 134.5, 133.7, 131.1, 129.9, 129.4, 129.2, 128.4, 127.5, 126.2, 
89.2, 58.0, 43.9; IR (ATR): υ = 3017, 2197, 1586, 1337, 1217, 1115, 1083, 969, 889, 
781, 743, 682 cm-1; MS (EI), m/z (relative intensity) 289 [M]+ (25), 182 (34), 149 (9), 
140 (31), 124 (100), 114 (37), 97 (18), 91 (15), 77 (25), 51 (15); MS (ESI), m/z 
290.04 [M+H]+; HRMS (ESI), m/z: [M+H]+ Calcd. for C15H13NOSCl 290.0401, 
found 290.0406. 
 
N-(3-Nitro-phenylethynyl)-S-methyl-S-phenylsulfoximine (90m) 
According to GPC, product 90m was prepared from 
S-methyl-S-phenylsulfoximine and 1-(bromoethynyl)-3-
nitrobenzene and obtained as a yellow oil in 46% yield after 
column chromatography on deactivated basic Al2O3 by using pentane/EtOAc = 3/2 as 
eluents. 1H NMR (600 MHz, CDCl3)  = 8.02 (d, J = 8.3 Hz, 2H), 7.98 (s, 1H), 7.92 
(dd, J = 8.2, 1.0 Hz, 1H), 7.74 (td, J = 7.1, 0.8 Hz, 1H), 7.65 (t, J = 7.1 Hz, 2H), 7.48 
(d, J = 7.7 Hz, 1H), 7.31 (t, J = 8.0 Hz, 1H), 3.31 (s, 3H); 13C NMR (150 MHz, 
CDCl3)  = 148.1, 137.1, 137.0, 134.7, 130.0, 128.9, 128.4, 127.7, 125.8, 120.6, 91.0, 
57.4, 44.0; IR (ATR): υ = 3076, 2205, 1524, 1341, 1217, 1121, 969, 914, 846, 737, 
678 cm-1; MS (EI), m/z (relative intensity) 300 [M]+ (2), 140 (10), 124 (41), 114 (14), 
109 (7), 91 (9), 77 (43), 51 (100); MS (ESI), m/z 301.06 [M+H]+; HRMS (ESI), m/z: 
[M+H]+ Calcd. for C15H13N2O3S 301.0641, found 301.0645. 
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N-(Triisopropylsilylethynyl)-S-methyl-S-phenylsulfoximine (90n) 
According to GPC, product 90n was prepared from 
S-methyl-S-phenylsulfoximine and (bromoethynyl)triisopropyl-
silane and obtained as a yellow solid in 61% yield after column 
chromatography on basic Al2O3 using pentane/EtOAc/Et3N = 25/25/1 as eluents.  
The melting point is 32.6–34.8 °C. 1H NMR (600 MHz, CDCl3)  = 7.98 (d, J = 7.4 
Hz, 2H), 7.68 (t, J = 7.4 Hz, 1H), 7.59 (t, J = 7.8 Hz, 2H), 3.23 (s, 3H), 0.93–0.88 (m, 
21H); 13C NMR (150 MHz, CDCl3)  = 137.0, 134.3, 129.7, 128.5, 102.1, 54.1, 43.3, 
18.8, 11.7; IR (ATR): υ = 2937, 2866, 2132, 1457, 1234, 1084, 978, 873, 743, 665 
cm-1; MS (EI), m/z (relative intensity) 335 [M]+ (5), 292 (100), 250 (12), 157 (6), 140 
(7), 124 (26), 97 (10), 91 (3), 77 (4), 51 (2); MS (ESI), m/z 336.18 [M+H]+; HRMS 
(ESI), m/z: [M+H]+ Calcd. for C18H30NOSSi 336.1812, found 336.1816. 
 
N-(2-Phenylvinylethynyl)-S-methyl-S-phenylsulfoximine (90o) 
According to GPC, product 90o was prepared from 
S-methyl-S-phenylsulfoximine and (E)-(4-bromobut-1-en-
3-yn-1-yl)benzene and obtained as a dark yellow solid in 24% yield after column 
chromatography on basic Al2O3 using pentane/EtOAc/Et3N = 25/25/1 as eluents. The 
melting point is 94.8–95.5 °C. 1H NMR (600 MHz, CDCl3)  = 8.02 (d, J = 7.5 Hz, 
2H), 7.71 (t, J = 7.4 Hz, 1H), 7.63 (t, J = 7.8 Hz, 2H), 7.29–7.24 (m, 4H), 7.17 (t, J = 
7.1 Hz, 1H), 6.64 (d, J = 16.0 Hz, 1H), 6.19 (d, J = 16.0 Hz, 1H), 3.27 (s, 3H); 13C 
NMR (150 MHz, CDCl3)  = 137.5 (2C), 136.9, 134.4, 129.9, 128.6, 128.4, 127.5, 
125.7, 110.4, 90.6, 58.8, 43.9; IR (ATR): υ = 3014, 2920, 2182, 1584, 1445, 1209, 
1088, 979, 740, 685 cm-1; MS (EI), m/z (relative intensity) 281 [M]+ (16), 141 (90), 
140 (97), 124 (100), 114 (34), 97 (24), 91 (24), 77 (36), 65 (11), 51 (27); MS (ESI), 
m/z 282.09 [M+H]+; HRMS (ESI), m/z: [M+H]+ Calcd. for C17H16NOS 282.0947, 
found 282.0947. 
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N-(4-Bromo-phenylethynyl)-S-isopropyl-S-phenylsulfoximine (90q) 
According to GPC, product 90q was prepared from 
S-isopropyl-S-phenylsulfoximine and 1-(bromoethynyl)-
4-bromobenzene and obtained as a yellow oil in 47% yield 
after column chromatography on deactivated basic Al2O3 using pentane/EtOAc/Et3N 
= 70/30/1 as eluents. 1H NMR (600 MHz, CDCl3)  = 8.02–7.86 (m, 2H), 7.77–7.66 
(m, 1H), 7.64–7.61 (m, 2H), 7.30–7.20 (m, 2H), 7.10–6.98 (m, 2H), 3.51 (dt, J = 13.6, 
6.8 Hz, 1H), 1.42 (d, J = 6.8 Hz, 3H), 1.32 (d, J = 6.9 Hz, 3H); 13C NMR (150 MHz, 
CDCl3)  = 134.4, 133.6, 132.7, 131.1, 130.1, 129.6, 125.0, 119.5, 89.7, 57.8, 56.6, 
16.2, 15.8; IR (ATR): υ = 3063, 2982, 2933, 2192, 1448, 1207, 1097, 874, 823, 726, 
686 cm-1; MS (EI), m/z (relative intensity) 363 ([M]+, 81Br) (24), 361 ([M]+, 79Br) (24), 
193 (4), 168 (14), 152 (86), 126 (92), 114 (34), 110 (100), 97 (5), 91 (24), 78 (50), 65 
(4), 51 (10); MS (ESI), m/z 364.02 ([M+H]+, 81Br); HRMS (ESI), m/z: ([M+H]+, 79Br) 
Calcd. for C17H17NOSBr 362.0209, found 362.0209. 
 
N-(4-Bromo-phenylethynyl)-S-(n-hexyl)-S-phenylsulfoximine (90r) 
According to GPC, product 90r was prepared from 
S-(n-hexyl)-S-phenylsulfoximine and 1-(bromoethynyl)-
4-bromobenzene and obtained as a pale yellow solid in 
64% yield after column chromatography on deactivated basic Al2O3 using 
pentane/EtOAc/Et3N = 90/10/1 to 70/30/1 as eluents. The melting point is 
105.3–106 °C. 1H NMR (600 MHz, CDCl3) = 7.98 (m, 2H), 7.74–7.68 (m, 1H), 
7.63 (m, 2H), 7.30–7.25 (m, 2H), 7.12–6.96 (m, 2H), 3.39–3.28 (m, 2H), 1.89–1.66 
(m, 2H), 1.43–1.29 (m, 2H), 1.28–1.15 (m, 4H), 0.84 (t, J = 7.0 Hz, 3H); 13C NMR 
(150 MHz, CDCl3) = 136.0, 134.4, 132.8, 131.2, 129.8, 129.1, 124.9, 119.6, 89.3, 
58.0, 56.0, 31.2, 27.8, 22.7, 22.4, 14.0; IR (ATR): υ = 3070, 2927, 2865, 2189, 1474, 
1206, 1086, 872, 807, 740, 684 cm-1; MS (EI), m/z (relative intensity) 430 [M]+ (6), 
211 (10), 193 (53), 126 (100), 114 (24), 110 (70), 78 (30), 51 (10); MS (ESI), m/z 
404.07 [M+H]+; Anal. Calcd. for C20H22BrNOS: C 59.41, H 5.48, N 3.46, found: C 
59.20, H 5.40, N 3.42. 
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N-(4-Bromo-phenylethynyl)-S,S-diphenylsulfoximine (90s) 
According to GPC, product 90s was prepared from 
S,S-diphenylsulfoximine and 1-(bromoethynyl)-4-bromo-
benzene and obtained as a yellow solid in 71% yield after 
column chromatography on deactivated basic Al2O3 using pentane/EtOAc/Et3N = 
70/30/1 as eluents. The melting point is 148.9–150 °C. 1H NMR (600 MHz, CDCl3)  
= 8.04 (d, J = 7.6 Hz, 4H), 7.62 (t, J = 7.4 Hz, 2H), 7.55 (t, J = 7.7 Hz, 4H), 7.26 (d, J 
= 8.4 Hz, 2H), 7.03 (d, J = 8.5 Hz, 2H); 13C NMR (150 MHz, CDCl3)  = 138.5, 
133.9, 132.8, 131.2, 129.7, 128.5, 124.8, 119.7, 89.0, 58.8; IR (ATR): υ = 3066, 2226, 
2190, 1224, 1096, 817, 730, 683cm-1; MS (EI), m/z (relative intensity) 228 (46), 202 
(59), 186 (100), 154 (47), 114 (33), 109 (47), 97 (24), 77 (36), 65 (20), 51 (40); MS 
(ESI), m/z 396.01 [M+H]+; HRMS (ESI), m/z: [M+Na]+ Calcd. for C20H14NOSBrNa 
417.9872, found 417.9872. 
 
N-(4-Bromo-phenylethynyl)-S-methyl-S-(4-bromo-phenyl)sulfoximine (90t) 
According to GPC, product 90t was prepared from 
S-(4-bromophenyl)-S-methylsulfoximine and 1-(bromo 
ethynyl)-4-bromobenzene and obtained as a pale 
yellow solid in 56% yield after column chromatography on deactivated basic Al2O3 
using pentane/EtOAc/Et3N = 70/30/1 as eluents. The melting point is 158.1–158.7 °C. 
1H NMR (600 MHz, CDCl3)  = 7.88 (d, J = 8.7 Hz, 2H), 7.78 (d, J = 8.7 Hz, 2H), 
7.30 (d, J = 8.5 Hz, 2H), 7.09 (d, J = 8.5 Hz, 2H), 3.28 (s, 3H); 13C NMR (150 MHz, 
CDCl3)  = 136.4, 133.3, 132.8, 131.3, 130.1, 130.0, 124.4, 120.0, 88.3, 58.5, 44.0; IR 
(ATR): υ = 3023, 2924, 2220, 2191, 1740, 1570, 1477, 1332, 1215, 1084, 979, 875, 
817, 783, 728 cm-1; MS (EI), m/z (relative intensity) 228 (35), 218 (26), 194 (19), 155 
(13), 114 (100), 75 (41), 63 (25), 51 (11); MS (ESI), m/z 411.88 ([M–H]-, 81Br); Anal. 
Calcd. for C15H11Br2NOS: C 43.61, H 2.68, N 3.39, found: C 43.89, H 2.574, N 3.23. 
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N-(4-Bromo-phenylethynyl)-S-methyl-S-(4-bromo-phenyl)sulfoximine (90u) 
According to GPC, product 90u was prepared from 
S-methyl-S-(4-nitrophenyl)sulfoximine and 
1-(bromoethynyl)-4-bromobenzene and obtained as a 
yellow solid in 56% yield by deactivated basic Al2O3 column chromatography using 
pentane/EtOAc/Et3N = 70/30/1 as eluents. The melting point is 145.9–146.7 °C. 1H 
NMR (600 MHz, CDCl3)  = 8.47 (d, J = 8.8 Hz, 2H), 8.23 (d, J = 8.8 Hz, 2H), 7.29 
(d, J = 8.5 Hz, 2H), 7.07 (d, J = 8.5 Hz, 2H), 3.34 (s, 3H); 13C NMR (150 MHz, 
CDCl3)  = 151.3, 143.3. 132.9, 131.3, 130.1, 125.1, 124.0, 120.4, 87.4, 58.9, 43.8; IR 
(ATR): υ = 3082, 2930, 2192, 1529, 1340, 1212, 1091, 979, 813, 735, 680 cm-1; MS 
(EI), m/z (relative intensity) 378 [M]+ (2), 228 (47), 193 (12), 185 (51), 169 (80), 114 
(100), 76 (22), 63 (23), 51 (32); MS (ESI), m/z 376.96 [M–H]-; Anal. Calcd. for 
C15H11BrN2O3S: C 47.51, H 2.92, N 7.39, found: C 47.54, H 2.685, N 7.28. 
 
N-(2-Bromo-phenylethynyl)-S,S-dimethylsulfoximine (90v) 
According to GPC, product 90v was prepared from 
S,S-dimethylsulfoximine and 1-(bromoethynyl)-2-bromobenzene 
and obtained as a yellow solid in 26% yield after column chromatography on 
deactivated basic Al2O3 by using pentane/EtOAc/Et3N =200/100/3 as eluents. The 
melting point is 122.8–123.9 °C. 1H NMR (400 MHz, CDCl3)  = 7.52 (d, J = 8.0 Hz, 
1H), 7.37 (dd, J = 7.7, 1.5 Hz, 1H), 7.18 (td, J = 7.6, 0.9 Hz, 1H), 7.02 (td, J = 7.8, 1.6 
Hz, 1H), 3.32 (s, 6H); 13C NMR (100 MHz, CDCl3) = 132.5, 132.1, 127.6, 127.2, 
127.0, 125.3, 93.0, 59.0, 41.2; IR (ATR): υ = 2924, 2182, 1591, 1483, 1250, 1032, 
752, 693 cm-1; MS (EI), m/z (relative intensity) 273 ([M]+, 81Br) (12), 271 ([M]+, 79Br) 
(12), 193 (5), 114 (71), 140 (7), 78 (19), 62 (100), 47 (8); MS (ESI), m/z 273.97 
[[M+H]+, 81Br]; Anal. Calcd. for C10H10NOSBr: C 44.13, H 3.70, N 5.15, found: 
C44.60, H 3.38, N 5.02. 
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7 List of abbreviation: 
Ac Acetyl 
acac Acetylacetonate 
t-amylOH 2-Methyl-2-butanol 
aq. Aqueous 
Ar Aryl 
atm The standard atmosphere 
BINAP 2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl 
Bn Benzyl 
Boc tert-Butyloxycarbonyl 
Bu Butyl 
Bz Benzoyl 
CDKs Cyclin-dependent kinases 
cod Cyclooctadiene 
conc. Concentrated 
COX Cyclooxygenase 
COXIB Cyclooxygenase-2 inhibitor 
Cp* Pentamethylcyclopentadienyl 
CPA Carboxypeptidase A 
CYP Cytochrome P450 
d Days 
dba Dibenzylideneacetone 
DCC Dicyclohexyl carbodiimide 
DCM Dichloromethane 
DMAP 4-Dimethylaminopyridine 
DME 1,2-Dimethoxyethane 
DMEDA N,N′-Dimethylethylenediamine 
DMF Dimethylformamide 
List of abbreviation 
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DMSO Dimethyl sulfoxide 
EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
Eq. Equation 
Equiv. Equivalent 
ER Estrogen receptor  
Et Ethyl 
FAAH Fatty acid amide hydrolase 
h Hours 
hERG The human Ether-à-go-go-Related Gene 
HIV Human Immunodeficiency Virus 
HOBt 1-Hydroxybenzotriazole 
i Iso 
IC50 The half maximal inhibitory concentration 
LTB4 Leukotriene B4  
m Meta 
M mol/L 
Me Methyl 
Mes Mesityl sulfonyl 
min Minutes 
Ms Methanesulfonyl 
n Normal 
NBS N-Bromosuccinimide 
NCS N-Chlorosuccinimide 
Nf Nonaflate 
Ns para-Nitrobenzenesulfonyl 
NSAID Non-steroidal anti-inflammatory drug 
p Para 
PEG-400 Polyethylene glycol 400 
PG Protecting group 
List of abbreviation 
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Ph Phenyl 
PMSF Phenylmethylsulfonyl fluoride 
Pr Propyl 
psi Pounds per square inch 
PTC Phase Transfer Catalyst 
rac Racemic 
r.t. Room temperature 
Ses Trimethylsilylethylsulfonyl 
t Tert 
TBHP tert-Butylhydroperoxide 
TBAF Tetra-n-butylammonium fluoride 
Temp. Temperature 
Tf Triflate 
THF Tetrahydrofuran 
TLC Thin layer chromatography 
TMS Trimethylsilyl 
TNF Tumor necrosis factors 
Tol para-Tolyl 
Ts Tosyl 
TSM Transition state mimic 
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